Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

16
results for

"Sae Hwan Lee"

Article category

Keywords

Publication year

"Sae Hwan Lee"

Original Articles

Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang
Clin Mol Hepatol 2025;31(3):810-822.
Published online January 17, 2025
DOI: https://doi.org/10.3350/cmh.2024.0819
Background/Aims
Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy and safety of BSV in patients with CHB who switched from long-term TDF to BSV. This study aimed to evaluate the outcome of a 48-week BSV therapy in patients with CHB who switched from long-term TDF treatment.
Methods
In this non-inferiority trial, 153 CHB patients treated with TDF for ≥48 weeks who had hepatitis B virus (HBV) DNA <20 IU/mL were randomized to receive either BSV 150 mg or TDF 300 mg for 48 weeks.
Results
The per-protocol analysis included 130 patients (BSV group, 64; TDF group, 66). The median duration of TDF use before enrollment was 4.14 years. After 48 weeks, 100.0% and 98.5% patients in the BSV and TDF groups, respectively, met the primary endpoint (HBV DNA <20 IU/mL), demonstrating the non-inferior antiviral efficacy of BSV to TDF (95% confidence interval –0.01 to 0.04; P>0.999), with a predefined margin of –0.18. The mean percentage changes in estimated glomerular filtration rates were slightly better in the BSV group (1.67±11.73%) than in the TDF group (–1.24±11.02%). The BSV group showed a significant improvement in bone turnover biomarkers compared to the TDF group; accordingly, hip and spine bone mineral density increased in the BSV group.
Conclusions
In patients with CHB receiving long-term TDF, switching to BSV may improve renal and bone safety with non-inferior antiviral efficacy compared to that of maintaining TDF.

Citations

Citations to this article as recorded by  Crossref logo
  • Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch
    Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu, Zhen-Yu Xu
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial”
    Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
    Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
  • 8,680 View
  • 157 Download
  • Crossref

Viral hepatitis

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C
Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang
Clin Mol Hepatol 2025;31(2):548-562.
Published online January 9, 2025
DOI: https://doi.org/10.3350/cmh.2024.0904
Background/Aims
Direct-acting antivirals (DAAs) effectively eradicate hepatitis C virus. This study investigated whether metabolic dysfunction influences the likelihood of fibrosis regression after DAA treatment in patients with chronic hepatitis C (CHC).
Methods
This multicenter, retrospective study included 8,819 patients diagnosed with CHC who were treated with DAAs and achieved a sustained virological response (SVR) between January 2014 and December 2022. Fibrosis regression was defined as a 20% reduction in noninvasive surrogates for liver fibrosis, such as liver stiffness (LS) measured by vibration-controlled transient elastography (VCTE) and the fibrosis-4 (FIB-4) score. Hypercholesterolemia (h-TC) was defined as >200 mg/dL.
Results
The median age of the study population was 59.6 years, with a predominance of male patients (n=4,713, 57.3%). Genotypes 1, 2, and others were confirmed in 3,872 (46.2%), 3,487 (41.6%), and 1,024 (12.2%) patients, respectively. Diabetes mellitus (DM) was present in 1,442 (17.2%) patients and the median LS was 7.50 kPa (interquartile range, 5.30–12.50). Multivariate analysis revealed that the presence of DM and pre-DAA h-TC were independently associated with a decreased probability of fibrosis regression by VCTE. Additionally, pre-DAA h-TC was independently associated with a decreased probability of fibrosis regression by the FIB-4.
Conclusions
Metabolic dysfunction has an unfavorable influence on fibrosis regression in patients with CHC who achieve SVR after DAA treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
    Yu‐Ping Chang, Jia‐Horng Kao, Chen‐Hua Liu
    Alimentary Pharmacology & Therapeutics.2025; 61(9): 1553.     CrossRef
  • Epidemiologic Characteristics of Chronic Hepatitis B and Coinfections with Hepatitis C Virus or Human Immunodeficiency Virus in South Korea: A Nationwide Claims-Based Study Using the Korean Health Insurance Review and Assessment Service Database
    Hyunwoo Oh, Won Sohn, Na Ryung Choi, Hyo Young Lee, Yeonjae Kim, Seung Woo Nam, Jae Yoon Jeong
    Pathogens.2025; 14(7): 715.     CrossRef
  • 7,187 View
  • 144 Download
  • 5 Web of Science
  • Crossref

Review

Viral hepatitis

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clin Mol Hepatol 2020;26(4):411-429.
Published online August 28, 2020
DOI: https://doi.org/10.3350/cmh.2020.0049
Clinical practice guidelines are important for guiding the management of specific diseases by medical practitioners, trainees, and nurses. In some cases, the guidelines are utilized as a reference for health policymakers in controlling diseases with a large public impact. With this in mind, practice guidelines for the management of chronic hepatitis B (CHB) have been developed in the United States, Europe, and Asian-Pacific regions to suggest the best-fit recommendations for each social and medical circumstance. Recently, the Korean Association for the Study of the Liver published a revised version of its clinical practice guidelines for the management of CHB. The guidelines included updated information based on newly available antiviral agents, the most recent opinion on the initiation and cessation of treatment, and updates for the management of drug resistance, partial virological response, and side effects. Additionally, CHB management in specific situations was comprehensively revised. This review compares the similarities and differences among the various practice guidelines to identify unmet needs and improve future recommendations.

Citations

Citations to this article as recorded by  Crossref logo
  • Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B
    David Z Pan, Cameron M Soulette, Abhishek Aggarwal, Dong Han, Nicholas van Buuren, Peiwen Wu, Becket Feierbach, Jaw-Town Lin, Cheng-Hao Tseng, Chi-Yi Chen, Bryan Downie, Hongmei Mo, Lauri Diehl, Li Li, Simon P Fletcher, Scott Balsitis, Ricardo Ramirez, Vi
    Gut.2025; 74(4): 628.     CrossRef
  • Limited Value of HBV‐RNA for Relapse Prediction After Nucleos(t)ide Analogue Withdrawal in HBeAg‐negative Hepatitis B Patients
    Valerie Ohlendorf, Maximilian Wübbolding, Christoph Höner zu Siederdissen, Birgit Bremer, Katja Deterding, Heiner Wedemeyer, Markus Cornberg, Benjamin Maasoumy
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • Overview of chronic hepatitis B management
    Angela Jun, Sherona Bau, John S. Kim, Susanne J. Phillips
    The Nurse Practitioner.2025; 50(1): 7.     CrossRef
  • Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study
    Xinye Qiu, Yue Yin, Shibin Zhang, Wei Liu
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Decreased incidence of hepatocellular carcinoma in non‐cirrhotic and low‐viral‐load chronic hepatitis B patients treated with nucleotide/nucleoside analogs
    Tyng‐Yuan Jang, Chia‐Yen Dai
    Advances in Digestive Medicine.2025;[Epub]     CrossRef
  • Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021
    Pojsakorn Danpanichkul, Kwanjit Duangsonk, Vincent L. Chen, Preenapun Saokhieo, Disatorn Dejvajara, Banthoon Sukphutanan, Majd B. Aboona, Chawin Lopimpisuth, Yanfang Pang, Andrew F. Ibrahim, Michael B. Fallon, Daniel Q. Huang, Donghee Kim, Amit G. Singal,
    Hepatology.2025; 82(5): 1274.     CrossRef
  • Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk
    Ankur Jindal, Manoj Kumar
    Hepatology International.2025; 19(4): 701.     CrossRef
  • Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis
    Yunmi Ko, Byeong Geun Song, Hyunjae Shin, Youngsu Park, Jeayeon Park, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Dong Hyun Sinn, Yoon Jun Kim, Jung-Hwan Yoon, Seung Shin Park, Moon Haeng Hur, Jeong-Hoon Lee
    Osteoporosis International.2025; 36(8): 1391.     CrossRef
  • Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
    Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Time for a globally unified chronic HBV terminology?
    Su Wang, Catherine Freeland, Seng Gee Lim, Hailemichael Desalegn, Chari Cohen, Harry L.A. Janssen
    JHEP Reports.2025; 7(12): 101570.     CrossRef
  • Chronic hepatitis B: Is it time for expanded antiviral treatment?
    Manish Manrai, Atul A Jha, Aditya V Pachisia, Saurabh Dawra
    World Journal of Virology.2025;[Epub]     CrossRef
  • Modeling the Impact of Treatment on Hepatitis B Burden: Mathematical Analysis and Simulation
    Jean Pierre II Kouenkam, Joseph Mbang, Gilbert Chendjou, Herieth Rwezaura, Jean Tchuenche
    Operations Research Forum.2025;[Epub]     CrossRef
  • Precision Management of Patients with HBV Infection
    Chih-Lin Lin, Jia-Horng Kao
    Current Hepatology Reports.2024; 23(1): 22.     CrossRef
  • Management of Hepatitis B in Pregnancy
    Jeanette Rios, Lital Aliasi-Sinai, Natalia Schmidt, Tatyana Kushner
    Current Hepatology Reports.2024; 23(2): 278.     CrossRef
  • Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B
    Tae Hyung Kim, Ji Hoon Kim, Hyung Joon Yim, Yeon Seok Seo, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun
    Gut and Liver.2024; 18(2): 305.     CrossRef
  • Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B
    Heechul Nam, Ji Won Han, Soon Kyu Lee, Hyun Yang, Hae Lim Lee, Pil Soo Sung, Myeong Jun Song, Jung Hyun Kwon, Jeong Won Jang, U‐Im Chang, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jin Mo Yang, Hee Yeon Kim
    Journal of Gastroenterology and Hepatology.2024; 39(8): 1673.     CrossRef
  • Hepatitis B surface antigen loss in chronic hepatitis B patients with low‐viral‐load
    Tyng‐Yuan Jang, Batbold Batsaikhan, Yo‐Chia Chen, Chia‐Yen Dai
    Journal of Gastroenterology and Hepatology.2024; 39(11): 2327.     CrossRef
  • Modern etiotropic therapy of chronic viral hepatitis B
    E. B. Bun'kova, N. A. Bileva, A. E. Bilev, M. I. Sinel'nikov
    Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH).2024; 14(4): 76.     CrossRef
  • Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients
    Wei-Chun Lin, Ke Lin, Ming-Kai Li, Xiao Liu, Yi-Fei Huang, Xing Wang, Bin Wu
    World Journal of Hepatology.2024; 16(11): 1321.     CrossRef
  • Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study
    Zehong Wang, Xuanxuan Wang, Li Zhou, Shaoyuan Shi, Yongli Hua, Yinong Feng
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Limited stability of Hepatitis B virus RNA in plasma and serum
    Valerie Ohlendorf, Birgit Bremer, Lisa Sandmann, Carola Mix, Tammo Tergast, Markus Cornberg, Heiner Wedemeyer, Katja Deterding, Benjamin Maasoumy
    Scientific Reports.2024;[Epub]     CrossRef
  • Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
    Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao
    Scientific Reports.2024;[Epub]     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study
    Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2023; 118(6): 1001.     CrossRef
  • Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
    Won Sohn, Yong-Han Paik
    Clinical and Molecular Hepatology.2023; 29(1): 182.     CrossRef
  • Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study
    Yoonseok Lee, Seryun Bae, Ji Hoon Kim, Minjung Kwak, So Yeon Jeon, Taehyung Kim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
    Journal of Clinical Medicine.2023; 12(2): 712.     CrossRef
  • Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis
    Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Sang Hoon Ahn, Chai Hong Rim
    Hepatology Communications.2023; 7(2): e0011.     CrossRef
  • miR-548c-3p targets TRIM22 to attenuate the Peg–IFN–α therapeutic efficacy in HBeAg-positive patients with chronic hepatitis B
    Ni Lin, Long Wang, Zhaopei Guo, Shaoying Guo, Can Liu, Jinpiao Lin, Songhang Wu, Siyi Xu, Hongyan Guo, Fenglin Fang, Ya Fu, Qishui Ou
    Antiviral Research.2023; 213: 105584.     CrossRef
  • Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
    Xingxin Zhang, Chenjian Gu, Qian Wei, Yirong Cao, Weimin She, Hong Shi, Youhua Xie, Jinsheng Guo
    Journal of Hepatocellular Carcinoma.2023; Volume 10: 599.     CrossRef
  • Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
    Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim
    Clinical and Molecular Hepatology.2023; 29(2): 482.     CrossRef
  • Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
    Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
    Hepatology.2023; 77(5): 1746.     CrossRef
  • Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
    Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(1): 99.     CrossRef
  • The urgency to expand the antiviral indications of general chronic hepatitis B patients
    Ping Fan, Lan-Qing Li, En-Qiang Chen
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
    Lanqing Li, Jing Zhou, Yujing Li, Fada Wang, Dongmei Zhang, Menglan Wang, Yachao Tao, Enqiang Chen
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study
    Heejoon Jang, Su Jong Yu, Hong Ghi Lee, Tae Min Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Jung-Hwan Yoon, Yoon Jun Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study
    Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
    Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
    Clinical and Molecular Hepatology.2023; 29(3): 794.     CrossRef
  • Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma
    Soo Ryang Kim, Soo Ki Kim
    Diagnostics.2023; 13(20): 3212.     CrossRef
  • The Connection between MiR-122 and Lymphocytes in Patients Receiving Treatment for Chronic Hepatitis B Virus Infection
    Marina Manea, Dimitri Apostol, Ileana Constantinescu
    Microorganisms.2023; 11(11): 2731.     CrossRef
  • Patient Preferences and Their Influence on Chronic Hepatitis B-A Review
    Lin Zhang, Yunyue Liu, Jinping Tian
    Patient Preference and Adherence.2023; Volume 17: 3119.     CrossRef
  • Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR‐122
    Yuh‐Jin Liang, Yu‐Wei Chiou, Abby Pei‐Ting Chiu, Ming‐Shi Shiao, Wei Teng, Chin‐Wei Lin, Mei‐Ling Cheng, Yen‐Hua Huang, Kung‐Hao Liang, Chien‐Wei Su, Chi‐Yu Lai, Chih‐Li Chen, Jaw‐Ching Wu
    Journal of Medical Virology.2023;[Epub]     CrossRef
  • Air pollution impede ALT normalization in chronic hepatitis B patients treated with nucleotide/nucleoside analogues
    Tyng-Yuan Jang, Chi-Chang Ho, Chih-Da Wu, Chia-Yen Dai, Pau-Chung Chen
    Medicine.2023; 102(43): e34276.     CrossRef
  • Effectiveness and Safety of Tenofovir Alafenamide in Treatment-Naïve and Treatment-Experienced Patients with Chronic Hepatitis B: Results of a Real-World Study from China
    Lan-Qing Li, Fa-Da Wang, Jing Zhou, Meng-Lan Wang, Yachao Tao, En-Qiang Chen
    Hepatitis Monthly.2023;[Epub]     CrossRef
  • Influence of Renal Function on the Single‐Dose Pharmacokinetics of Besifovir, a Novel Antiviral Agent for theTreatment of Hepatitis B Virus Infection
    Jun Gi Hwang, Yu Kyong Kim, Young‐sim Choi, Soon Kil Kwon, Joung‐Ho Han, Min Kyu Park
    The Journal of Clinical Pharmacology.2022; 62(1): 46.     CrossRef
  • Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection
    Zhenyu Zhong, Weiting Liao, Lingyu Dai, Xiaojie Feng, Guannan Su, Yu Gao, Qiuying Wu, Peizeng Yang
    Annals of the Rheumatic Diseases.2022; 81(4): 584.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • Correlation of hepatitis B surface antigen expression with clinicopathological and biochemical parameters in liver biopsies: A comprehensive study
    Anil Alpsoy, Haydar Adanir, Zeynep Bayramoglu, Gulsum Ozlem Elpek
    World Journal of Hepatology.2022; 14(1): 260.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries
    Ben Kang, Dae Yong Yi, Byung-Ho Choe
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis
    Seunghwan Shin, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Diagnostics.2022; 12(2): 441.     CrossRef
  • Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study
    Young Eun Chon, Soo Young Park, Seung Up Kim, Han Pyo Hong, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2022; 29(4): 289.     CrossRef
  • A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients
    Hyung Joon Kim, Ju Hyun Kim, Jong Eun Yeon, Yeon Seok Seo, Jeong Won Jang, Yong Kyun Cho, Byoung Kuk Jang, Byung Hoon Han, Changhyeong Lee, Joon Hyeok Lee, Jung-Hwan Yoon, Kang Mo Kim, Moon Young Kim, Do Young Kim, Neung Hwa Park, Eun Young Cho, June Sung
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients
    Han Ah Lee, Hyun Woong Lee, Younhee Park, Hyon-Suk Kim, Yeon Seok Seo
    Journal of Clinical Medicine.2022; 11(6): 1729.     CrossRef
  • Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL
    Hankil Lee, Sungin Jang, Sang Hoon Ahn, Beom Kyung Kim
    Hepatology International.2022; 16(2): 294.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(5): 758.     CrossRef
  • Fibrotic burden during antiviral therapy for chronic hepatitis B, not ALT level, independently predicts liver cancer risk
    David Sooik Kim, Beom Kyung Kim, Yeon Seok Seo, Byung Seok Kim, Byoung Kuk Jang, Sang Gyune Kim, Ki Tae Suk, Jin‐Woo Lee, Soung Won Jeong, Seung Up Kim
    Liver International.2022; 42(8): 1902.     CrossRef
  • Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study
    Jihye Lim, Jung‐Bok Lee, Jihyun An, Gi‐Won Song, Kang Mo Kim, Han Chu Lee, Ju Hyun Shim
    Journal of Viral Hepatitis.2022; 29(9): 756.     CrossRef
  • Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Jin‐Ha Yoon, Beom Kyung Kim
    Hepatology Communications.2022; 6(9): 2455.     CrossRef
  • Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2022; 103: 122.     CrossRef
  • [Retracted] Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment
    Haixia Sun, Yinhui Liu, Yufeng Zhang, Yusheng Jie, Yuankai Wu, Zhanyi Li, Xuxia Wei, Xiangyong Li, Bing Niu
    BioMed Research International.2022;[Epub]     CrossRef
  • Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis
    Ran Cheng, Xiaoyuan Xu
    Journal of Hepatocellular Carcinoma.2022; Volume 9: 987.     CrossRef
  • Response to Liao et al.
    Byungyoon Yun, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(10): 1718.     CrossRef
  • Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
    Hyung Joon Yim, Ji Hoon Kim, Yong Kyun Cho, Young Oh Kweon, Hyun Chin Cho, Jae Seok Hwang, Changhyeong Lee, Moon Soo Koh, Yang-Hyun Baek, Young-Min Park, Jeong-Hoon Lee, Seung Up Kim, Min-Kyu Kang, Neung Hwa Park, June Sung Lee, Young Eun Chon, Gab Jin Ch
    Drug Design, Development and Therapy.2022; Volume 16: 3263.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients
    Ji Hun Lee, Seung Kak Shin, Seong Hee Kang, Tae Hyung Kim, Hyung Joon Yim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Oh Sang Kwon, Soon Ho Um, Kwan Soo Byun
    Journal of Clinical Medicine.2022; 11(22): 6613.     CrossRef
  • Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
    Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
    Clinical and Molecular Hepatology.2022; 28(4): 876.     CrossRef
  • Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies
    Jonggi Choi, Young‐Suk Lim
    The Kaohsiung Journal of Medical Sciences.2021; 37(4): 262.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
    Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
    Cancers.2021; 13(14): 3424.     CrossRef
  • No Uniformity in the References of Clinical Practice Guidelines for Bariatric Surgery: a Review of 3 Similar Guidelines Published in 2020.
    Mark J. R. Smeets, Ronald S. L. Liem
    Obesity Surgery.2021; 31(12): 5427.     CrossRef
  • Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Hepatology International.2021; 15(5): 1083.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Critical Updates on Chronic Hepatitis B Virus Infection in 2021
    Cyriac A Philips, Rizwan Ahamed, Jinsha K Abduljaleel, Sasidharan Rajesh, Philip Augustine
    Cureus.2021;[Epub]     CrossRef
  • Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
    David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Novel Therapies of Hepatitis B and D
    Iman Waheed Khan, Mati Ullah Dad Ullah, Mina Choudhry, Mukarram Jamat Ali, Muhammad Ashar Ali, Sam L. K. Lam, Pir Ahmad Shah, Satinder Pal Kaur, Daryl T. Y. Lau
    Microorganisms.2021; 9(12): 2607.     CrossRef
  • Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B
    Yoon Seok Lee, Soo Min Bang, Young-Sun Lee
    Journal of Clinical Medicine.2021; 10(11): 2320.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients
    Hye Yeon Chon, Sang Hoon Ahn, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Dong Hyun Sinn, Seung Up Kim
    Hepatology International.2021; 15(6): 1328.     CrossRef
  • Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination
    Fátima Higuera-de la Tijera, Alfredo Servín-Caamaño, Luis Servín-Abad
    World Journal of Gastroenterology.2021; 27(26): 4004.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • 19,319 View
  • 1,478 Download
  • 83 Web of Science
  • Crossref

Original Articles

Viral hepatitis

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
Young Min Kim, Suk Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Myeong Jun Song, Ji Woong Jang, Soon Young Ko, Jae Dong Lee
Clin Mol Hepatol 2018;24(3):311-318.
Published online June 4, 2018
DOI: https://doi.org/10.3350/cmh.2017.0070
Background/Aims
Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection.
Methods
We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area.
Results
A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27–96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients.
Conclusions
A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection.

Citations

Citations to this article as recorded by  Crossref logo
  • Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study
    Ik Sung Choi, Kwang Min Kim, Sang Goon Shim
    Arab Journal of Gastroenterology.2021; 22(1): 23.     CrossRef
  • Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
    Young Joo Park, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Young Mi Hong, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho
    Gut and Liver.2021; 15(3): 440.     CrossRef
  • Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
    Carlo Smirne, Antonio D'Avolio, Mattia Bellan, Alessandro Gualerzi, Maria G. Crobu, Mario Pirisi
    Pharmacology Research & Perspectives.2021;[Epub]     CrossRef
  • Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment
    Jennifer J. Lin, Catrina M. Loucks, Jessica N. Trueman, Britt I. Drögemöller, Galen E.B. Wright, Eric M. Yoshida, Jo-Ann Ford, Samuel S. Lee, Richard B. Kim, Bandar Al-Judaibi, Ute I. Schwarz, Alnoor Ramji, Edward Tam, Colin J. Ross, Bruce C. Carleton
    Biomedicine & Pharmacotherapy.2021; 143: 112195.     CrossRef
  • Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin
    Chi-Ching Chen, Shui-Yi Tung, Kuo-Liang Wei, Chien-Heng Shen, Te-Sheng Chang, Wei-Ming Chen, Huang-Wei Xu, Chih-Wei Yen, Yi-Hsing Chen, Sheng-Nan Lu, Chao-Hung Hung
    Journal of the Formosan Medical Association.2020; 119(1): 532.     CrossRef
  • Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
    Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2020; 12(11): 3414.     CrossRef
  • Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
    Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
    Gut and Liver.2020; 14(6): 775.     CrossRef
  • Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium
    Chung-Feng Huang, Etsuko Iio, Dae Won Jun, Eiichi Ogawa, Hidenori Toyoda, Yao-Chun Hsu, Hiroaki Haga, Shinji Iwane, Masaru Enomoto, Dong Hyun Lee, Grace Wong, Chen-Hua Liu, Toshifumi Tada, Wan-Long Chuang, Ramsey Cheung, Jun Hayashi, Cheng-Hao Tseng, Sato
    Hepatology International.2019; 13(5): 587.     CrossRef
  • Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
    Young-Hwan Ahn, Hyungcheol Park, Myeon Jae Lee, Dong Hyun Kim, Sung Bum Cho, Eunae Cho, Chung Hwan Jun, Sung Kyu Choi
    Gut and Liver.2019; 13(5): 549.     CrossRef
  • Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
    Jong Eun Yeon
    Clinical and Molecular Hepatology.2018; 24(3): 294.     CrossRef
  • Ribavirin/sofosbuvir

    Reactions Weekly.2018; 1727(1): 247.     CrossRef
  • 10,636 View
  • 206 Download
  • 11 Web of Science
  • Crossref

Viral hepatitis

Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae
Clin Mol Hepatol 2017;23(1):51-56.
Published online March 16, 2017
DOI: https://doi.org/10.3350/cmh.2016.0053
Background/Aims
The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection.
Methods
We retrospectively analyzed clinical data from chronic HCV genotype Ib patients treated with DCV+ASV from August 2015 to September 2016 at five hospitals in the Daejeon-Chungcheong area.
Results
A total of 152 patients were examined for resistance associated variants (RAVs). Among them, 15 (9.9%) were positive for Y93 and one (0.7%) was positive for L31. Of 126 patients treated with DCV+ASV, 83 patients completed treatment and 76 patients were included in safety and efficacy analysis. Five (6.6%) were positive for Y93 and 12 (15.8%) exhibited cirrhotic change. DCV+ASV was the first-line treatment for 58 (76.3%) patients. Eleven (14.5%) patients relapsed after previous treatment that included interferon and seven (9.2%) of these patients were found to be intolerant of interferon. Adverse events occurred in 10 (13.2%) patients and two patients stopped the medication because of severe itching and skin rash. SVR12 was 89.5% (68/76) in all patients and 91.5% (65/71) in RAV-negative patients.
Conclusions
DCV+ASV showed good efficacy in patients with HCV Ib infection in Korea. Close monitoring is needed for severe adverse events and treatment failure, which were uncommon.

Citations

Citations to this article as recorded by  Crossref logo
  • The Incidence and Care Cascade of the Hepatitis C Virus in Korea
    Young Eun Chon, Aejeong Jo, Eileen L. Yoon, Jonghyun Lee, Ho Gyun Shin, Min Jung Ko, Dae Won Jun
    Gut and Liver.2023; 17(6): 926.     CrossRef
  • Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
    Young-Hwan Ahn, Heirim Lee, Ji Eun Han, Hyo Jung Cho, Jae Youn Cheong, Bumhee Park, Soon Sun Kim
    Journal of Liver Cancer.2022; 22(2): 125.     CrossRef
  • Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea
    Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon‐Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Nam Ik Han, Seok‐Hwan Kim, Myeong Jun Song, Pil Soo Sung,
    Journal of Medical Virology.2019; 91(6): 1104.     CrossRef
  • Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
    Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti
    Clinical and Molecular Hepatology.2019; 25(1): 30.     CrossRef
  • Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
    Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song
    Gut and Liver.2019; 13(2): 191.     CrossRef
  • Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
    Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
    The Korean Journal of Internal Medicine.2019; 34(4): 794.     CrossRef
  • Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test
    Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong
    Journal of Medical Virology.2019; 91(12): 2158.     CrossRef
  • An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
    Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang
    Clinical and Molecular Hepatology.2019; 25(4): 400.     CrossRef
  • Systematic review with meta‐analysis: effectiveness and tolerability of interferon‐free direct‐acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia
    F. Ji, B. Wei, Y. H. Yeo, E. Ogawa, B. Zou, C. D. Stave, Z. Li, S. Dang, N. Furusyo, R. C. Cheung, M. H. Nguyen
    Alimentary Pharmacology & Therapeutics.2018; 47(5): 550.     CrossRef
  • Early development of de novo hepatocellular carcinoma after direct‐acting agent therapy: Comparison with pegylated interferon‐based therapy in chronic hepatitis C patients
    S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.‐Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.‐H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K
    Journal of Viral Hepatitis.2018; 25(10): 1189.     CrossRef
  • Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
    Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
    Gut and Liver.2018; 12(3): 324.     CrossRef
  • Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
    Petra E de Ruiter, Yashna Gadjradj, Robert J de Knegt, Herold J Metselaar, Jan NM Ijzermans, Luc JW van der Laan
    World Journal of Transplantation.2018; 8(5): 156.     CrossRef
  • Asunaprevir/daclatasvir

    Reactions Weekly.2017; 1653(1): 56.     CrossRef
  • Global elimination of hepatitis C virus infection: Progresses and the remaining challenges
    Reza Taherkhani, Fatemeh Farshadpour
    World Journal of Hepatology.2017; 9(33): 1239.     CrossRef
  • 10,523 View
  • 215 Download
  • 12 Web of Science
  • Crossref

Hepatic neoplasm

Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma
Kil Hyo Park, Soon Ha Kwon, Yong Sub Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Yong Jae Kim
Clin Mol Hepatol 2015;21(2):158-164.
Published online June 26, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.2.158
Background/Aims

The predictive role of contrast-enhanced ultrasonography (CEUS) before performing transarterial chemoembolization (TACE) has not been determined. We assessed the possible predictive factors of CEUS for the response to TACE.

Methods

Seventeen patients with 18 hepatocellular carcinoma (HCC) underwent TACE. All of the tumors were studied with CEUS before TACE using a second-generation ultrasound contrast agent (SonoVue®, Bracco, Milan, Italy). The tumor response to TACE was classified with a score between 1 and 4 according to the remaining enhancing-tumor percentage based on modified response evaluation criteria in solid tumors (mRECIST): 1, enhancing tumor <25%; 2, 25%≤enhancing tumor<50%; 3, 50%≤enhancing tumor<75%; and 4, enhancing tumor≥75%). A score of 1 was defined as a "good response" to TACE. The predictive factors for the response to TACE were evaluated during CEUS based on the maximum tumor diameter, initial arterial enhancing time, arterial enhancing duration, intensity of arterial enhancement, presence of a hypoenhanced pattern, and the feeding artery to the tumor.

Results

The median tumor size was 3.1 cm. The distribution of tumor response scores after TACE in all tumors was as follows: 1, n=11; 2, n=4; 3, n=2; and 4, n=1. Fifteen tumors showed feeding arteries. The presence of a feeding artery and the tumor size (≤5 cm) were the predictive factors for a good response (P=0.043 and P=0.047, respectively).

Conclusions

The presence of a feeding artery and a tumor size of less than 5 cm were the predictive factors for a good response of HCC to TACE on CEUS.

Citations

Citations to this article as recorded by  Crossref logo
  • A novel stratification scheme combined with internal arteries in CT imaging for guiding postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a retrospective cohort study
    Xinming Li, Xiangjing Liang, Zhipeng Li, Jianye Liang, Zhendong Qi, Liming Zhong, Zhijun Geng, Wen Liang, Xianyue Quan, Changhong Liang, Zaiyi Liu
    International Journal of Surgery.2024; 110(5): 2556.     CrossRef
  • Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging
    Jie Peng, Shuai Kang, Zhengyuan Ning, Hangxia Deng, Jingxian Shen, Yikai Xu, Jing Zhang, Wei Zhao, Xinling Li, Wuxing Gong, Jinhua Huang, Li Liu
    European Radiology.2020; 30(1): 413.     CrossRef
  • Contrast-enhanced US for the Interventional Radiologist: Current and Emerging Applications
    Christopher D. Malone, David T. Fetzer, Wayne L. Monsky, Malak Itani, Vincent M. Mellnick, Philip A. Velez, William D. Middleton, Michalakis A. Averkiou, Raja S. Ramaswamy
    RadioGraphics.2020; 40(2): 562.     CrossRef
  • Diagnostic Value of High Frame Rate Contrast-enhanced Ultrasonography and Post-processing Contrast Vector Imaging for Evaluation of Focal Liver Lesions: A Feasibility Study
    Jeongin Yoo, Jeong Min Lee
    Ultrasound in Medicine & Biology.2020; 46(9): 2254.     CrossRef
  • Another Face of Contrast-Enhanced Ultrasonography: A Diagnostic Tool for Cirrhosis
    Soung Won Jeong
    Gut and Liver.2017; 11(1): 9.     CrossRef
  • Focal Liver Lesions: Real‐time 3‐Dimensional Contrast‐Enhanced Ultrasonography Compared With 2‐Dimensional Contrast‐Enhanced Ultrasonography and Magnetic Resonance Imaging
    Jung‐chieh Lee, Kun Yan, San‐kan Lee, Wei Yang, Min‐hua Chen
    Journal of Ultrasound in Medicine.2017; 36(10): 2015.     CrossRef
  • Intraoperative 3D contrast-enhanced ultrasound (CEUS): a prospective study of 50 patients with brain tumours
    Felix Arlt, Claire Chalopin, Andrea Müns, Jürgen Meixensberger, Dirk Lindner
    Acta Neurochirurgica.2016; 158(4): 685.     CrossRef
  • 10,657 View
  • 120 Download
  • 10 Web of Science
  • Crossref

Viral hepatitis

The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients
Hee Jae Jung, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Boo Sung Kim
Clin Mol Hepatol 2014;20(1):38-46.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.38
Background/Aims

Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was to determine the association between CHC treatment response and lipid profile and IR change during treatment.

Methods

In total, 203 CHC patients were reviewed retrospectively between January 2005 and December 2011 at Soon Chun Hyang University Hospital. The lipid profile, homeostasis model for assessment (HOMA) of IR (HOMA-IR), and HOMA of β cells (HOMA-β) were evaluated before interferon plus ribavirin therapy (BTx), at the end of treatment (DTx), and 24 weeks after the end of treatment (ATx).

Results

A sustained virologic response (SVR) was achieved by 81% of all patients (49/60), 60% (n=36) of whom possessed genotype 1, with the remainder being non-genotype-1 (40%, n=24). Apart from age, which was significantly higher in the non-SVR group (SVR, 48.0±11.2 years, mean±SD; non-SVR, 56.6±9.9 years; P<0.01), there were no significant differences in the baseline characteristics between the SVR and non-SVR groups. In the SVR group, low density lipoprotein-cholesterol (LDL-C) had significantly changed at DTx and ATx compared to BTx. In addition, HOMA-IR and HOMA-β were significantly changed at DTx in the SVR group. Among those with a high baseline insulin resistance (HOMA-IR >2.5), HOMA-IR was significantly changed at DTx in the SVR group.

Conclusions

LDL-C appears to be associated with HCV treatment in SVR patients. Furthermore, eradication of HCV may improve whole-body IR and insulin hypersecretion, as well as high baseline insulin resistance (HOMA-IR >2.5).

Citations

Citations to this article as recorded by  Crossref logo
  • Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals
    Nehal K. Abdel Fattah, Sara M. Shaheen, Osama A. Ahmed, Kadry Elsaeed, Nagwa A. Sabri
    F1000Research.2022; 11: 649.     CrossRef
  • Lipid profile changes after direct acting antiviral treatment in different genotypes of chronic hepatitis C virus‐infected patients
    Cheng‐Heng Lin, Jyh‐Jou Chen, Pei‐Lun Lee, Hung‐Da Tung, Chun‐Ta Cheng, Hsu‐Ju Kao, Yu‐Hsun Wu, Mai‐Gio Pang, Tang‐Wei Chuang
    Advances in Digestive Medicine.2021; 8(3): 139.     CrossRef
  • Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir
    Mahmoud Abdo, Ahmed Rabiee, Zeinab Abdellatif, Shereen Abdel Alem, Ahmed Moustafa
    European Journal of Gastroenterology & Hepatology.2021; 33(12): 1588.     CrossRef
  • The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments
    Phumelele Yvonne Siphepho, Yi-Ting Liu, Ciniso Sylvester Shabangu, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Ming-Lung Yu, Shu-Chi Wang
    Biomedicines.2021; 9(10): 1491.     CrossRef
  • Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment
    Mostafa Elhelbawy, Wael Abdel-Razek, Ayman Alsebaey, Mohamed Hashim, Hassan Elshenawy, Imam Waked
    European Journal of Gastroenterology & Hepatology.2019; 31(1): 16.     CrossRef
  • Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C
    Yi-Hao Yen, Kwong-Ming Kee, Chien-Hung Chen, Tsung-Hui Hu, Sheng-Nan Lu, Jing-Houng Wang, Chao-Hung Hung, Tatsuo Kanda
    PLOS ONE.2019; 14(1): e0208858.     CrossRef
  • Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients
    Ayush Jain, Bhupinder Singh Kalra, Siddharth Srivastava, Shalini Chawla
    Indian Journal of Gastroenterology.2019; 38(1): 39.     CrossRef
  • Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters
    Mary-Anne Doyle, Chrissi Galanakis, Erin Mulvihill, Angela Crawley, Curtis L. Cooper
    Cells.2019; 8(3): 252.     CrossRef
  • Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
    Mary-Anne Doyle, Terry Lee, Joel Singer, Angela Crawley, Marina Klein, Curtis Cooper
    Open Forum Infectious Diseases.2019;[Epub]     CrossRef
  • HCV treatment with direct acting antivirals improves the insulin sensitivity
    Ayman Alsebaey, Mostafa Elhelbawy, Wael Abdel-Razek, Mohammed Hashim, Hassan Elshenawy, Imam Waked
    Expert Review of Anti-infective Therapy.2019; 17(9): 749.     CrossRef
  • Effect of HCV treatment response on insulin resistance: A systematic review and meta‑analysis
    Jing‑Hong Hu, Ming‑Ling Chang, Nai‑Jen Liu, Chu‑Ting Yeh, Tung‑Jung Huang
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study
    Goki Suda, Jun Ito, Atsushi Nagasaka, Yoshiya Yamamoto, Ken Furuya, Munenori Okamoto, Katsumi Terashita, Tomoe Kobayashi, Izumi Tsunematsu, Junichi Yoshida, Takashi Meguro, Masatsugu Ohara, Naoki Kawagishi, Megumi Kimura, Machiko Umemura, Takaaki Izumi, Y
    Hepatology Research.2018;[Epub]     CrossRef
  • Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b
    Takeshi Chida, Kazuhito Kawata, Kazuyoshi Ohta, Erika Matsunaga, Jun Ito, Shin Shimoyama, Satoru Yamazaki, Hidenao Noritake, Tetsuro Suzuki, Takafumi Suda, Yoshimasa Kobayashi
    Gut and Liver.2018; 12(2): 201.     CrossRef
  • Exploring lipid and apolipoprotein levels in chronic hepatitis C patients according to their response to antiviral treatment
    Gilmar de Souza Lacerda, Thalia Medeiros, Natalia Fonseca do Rosário, Regina Helena Saramago Peralta, Mauro Jorge Cabral-Castro, Eliane Bordalo Cathalá Esberard, Thaís Guaraná de Andrade, Analúcia Rampazzo Xavier, Andrea Alice Silva
    Clinical Biochemistry.2018; 60: 17.     CrossRef
  • Hepatitis C Virus Eradication with New Interferon‐Free Treatment Improves Metabolic Profile in Hepatitis C Virus‐Related Liver Transplant Recipients
    Junaid Beig, David Orr, Barry Harrison, Edward Gane
    Liver Transplantation.2018; 24(8): 1031.     CrossRef
  • Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
    Naoki Kawagishi, Goki Suda, Akinobu Nakamura, Megumi Kimura, Osamu Maehara, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Muts
    PLOS ONE.2018; 13(12): e0209615.     CrossRef
  • The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C
    Batbold Batsaikhan, Ching-I Huang, Ming-Lun Yeh, Chung-Feng Huang, Nei-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang, Jin-Ching Lee, Chia-Yen Dai
    Oncotarget.2018; 9(30): 21313.     CrossRef
  • Hepatitis C virus and atherosclerosis: A legacy after virologic cure?
    M.F. Bassendine, S.U. Nielsen, S.H. Bridge, D.J. Felmlee, D.A. Sheridan, C.J. Packard, R.D. Neely
    Clinics and Research in Hepatology and Gastroenterology.2017; 41(1): 25.     CrossRef
  • Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review
    Anne-Claire Desbois, Patrice Cacoub
    World Journal of Gastroenterology.2017; 23(9): 1697.     CrossRef
  • Endemic hepatitis B and C virus areas are associated with lower prevalence of hyperlipidemia: Ecological and cross‐sectional studies
    Chao‐Tung Chen, Wei‐Cheng Huang, Jing‐Houng Wang, Chuan‐Mo Lee, Chao‐Hung Hung, Lin‐San Tsai, Shu‐Chuan Chen, Sheng‐Che Lin, Sheng‐Nan Lu, Kwong‐Ming Kee
    Advances in Digestive Medicine.2017; 4(2): 54.     CrossRef
  • Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin
    Beti Todorovska, Nenad Joksimovic, Viktorija Caloska-Ivanova, Magdalena Dimitrova-Genadieva, Meri Trajkovska, Elena Curakova, Sanja Kiprijanovska, Beti Zafirova-Ivanovska, Vladimir Serafimoski
    PRILOZI.2017; 38(1): 25.     CrossRef
  • Diabetes and Glucose Metabolism in Thalassemia Major: An Update
    Vincenzo De Sanctis, Ashraf T Soliman, Heba Elsedfy, Alessia Pepe, Christos Kattamis, Mohamed El Kholy, Mohamed Yassin
    Expert Review of Hematology.2016; 9(4): 401.     CrossRef
  • Change in insulin resistance according to virological response during antiviral treatment for hepatitis C virus infection
    Cheng‐Hao Tseng, Yao‐Chun Hsu, Chi‐Yang Chang, Chih‐Wen Lin, Jaw‐Town Lin, Lein‐Ray Mo
    Advances in Digestive Medicine.2016; 3(2): 43.     CrossRef
  • Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir
    Sebastian Bernuth, Eray Yagmur, Detlef Schuppan, Martin F. Sprinzl, Anca Zimmermann, Arno Schad, Jens M. Kittner, Veronika Weyer, Johanna Knapstein, Jörn M. Schattenberg, Marcus A. Wörns, Peter R. Galle, Tim Zimmermann
    Digestive and Liver Disease.2016; 48(3): 291.     CrossRef
  • Factors Associated with Insulin Resistance in Patients with Chronic HCV Genotype 1 Infection without Obesity or Type 2 Diabetes
    Lucivalda Pereira Magalhães Oliveira, Rosangela Passos de Jesus, Ramona Souza Silva Baqueiro Boulhosa, Thiago Onofre, Carlos Mauricio Cardeal Mendes, Leonardo Vinhas, Dan Linetzky Waitzberg, Denise Carneiro Lemaire, Lourianne N. Cavalcante, Andre Castro L
    Journal of the American College of Nutrition.2016; 35(5): 436.     CrossRef
  • Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C
    Magnus Hedenstierna, Ali Nangarhari, Ola Weiland, Soo Aleman
    Clinical Infectious Diseases.2016; 63(6): 723.     CrossRef
  • Genotype specific peripheral lipid profile changes with hepatitis C therapy
    Mark R Pedersen, Amit Patel, David Backstedt, Myunghan Choi, Anil B Seetharam
    World Journal of Gastroenterology.2016; 22(46): 10226.     CrossRef
  • Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES
    Adeel A. Butt, Peng Yan, Tracey G. Simon, Raymond T. Chung, Abdul-Badi Abou-Samra
    BMC Infectious Diseases.2015;[Epub]     CrossRef
  • A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients
    Sadia Qamar Arain, Farah Naz Talpur, Naseem Aslam Channa
    Lipids in Health and Disease.2015;[Epub]     CrossRef
  • Improvement of glucose and lipid metabolism with pegylated interferon-α plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus
    Shao Qing, Dong Ji, Bing Li, Fan Li, Yudong Wang, Xioaxia Niu, Binfang Ling, Yuhua Meng, George Lau, Guofeng Chen
    Annals of Saudi Medicine.2015; 35(4): 293.     CrossRef
  • Liver steatosis in hepatitis C patients
    Emilio González-Reimers
    World Journal of Hepatology.2015; 7(10): 1337.     CrossRef
  • 11,870 View
  • 86 Download
  • 32 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

The secondary prophylactic efficacy of beta-blocker after endoscopic gastric variceal obturation for first acute episode of gastric variceal bleeding
Moon Han Choi, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Yu Ri Seo, Min Jin Kim, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Boo Sung Kim
Clin Mol Hepatol 2013;19(3):280-287.
Published online September 30, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.3.280
Background/Aims

The most appropriate treatment for acute gastric variceal bleeding (GVB) is currently endoscopic gastric variceal obturation (GVO) using Histoacryl®. However, the secondary prophylactic efficacy of beta-blocker (BB) after GVO for the first acute episode of GVB has not yet been established. The secondary prophylactic efficacy of BB after GVO for the first acute episode of GVB was evaluated in this study.

Methods

Ninety-three patients at Soonchunhyang University Hospital with acute GVB who received GVO using Histoacryl® were enrolled between June 2001 and March 2010. Among these, 42 patients underwent GVO alone (GVO group) and 51 patients underwent GVO with adjuvant BB therapy (GVO+BB group). This study was intended for patients in whom a desired heart rate was reached. The rates of rebleeding-free survival and overall survival were calculated for the two study groups using Kaplan-Meyer analysis and Cox's proportional-hazards model.

Results

The follow-up period after the initial eradication of gastric varices was 18.14±25.22 months (mean±SD). During the follow-up period, rebleeding occurred in 10 (23.8%) and 21 (41.2%) GVO and GVO+BB patients, respectively, and 39 patients died [23 (54.8%) in the GVO group and 16 (31.4%) in the GVO+BB group]. The mean rebleeding-free survival time did not differ significantly between the GVO and GVO+BB groups (65.40 and 37.40 months, respectively; P=0.774), whereas the mean overall survival time did differ (52.54 and 72.65 months, respectively; P=0.036).

Conclusions

Adjuvant BB therapy after GVO using Histoacryl® for the first acute episode of GVB could decrease the mortality rate relative to GVO alone. However, adjuvant BB therapy afforded no benefit for the secondary prevention of rebleeding in GV.

Citations

Citations to this article as recorded by  Crossref logo
  • A randomized controlled trial comparing large-volume band ligator and cyanoacrylate injection in the endoscopic management of actively bleeding gastric varices
    Ding Shi, Guojing Xu, Weijin Pan
    Scientific Reports.2025;[Epub]     CrossRef
  • Risk Factors for Rebleeding After Endoscopic Injection of Cyanoacrylate Glue for Gastric Varices: A Systematic Review and Meta-Analysis
    Yihuan Hu, Mei Zhou, Deliang Liu, Jian Gong
    Digestive Diseases and Sciences.2024; 69(8): 2890.     CrossRef
  • Liver stiffness-spleen diameter to platelet ratio score (LSPS model) predicts variceal rebleeding for cirrhotic patients
    Xixuan Wang, Hao Han, Jian Yang, Yang Cheng, Xiaochun Yin, Lihong Gu, Jiangqiang Xiao, Yi Wang, Xiaoping Zou, Lei Wang, Ming Zhang, Yuzheng Zhuge, Feng Zhang
    European Journal of Gastroenterology & Hepatology.2023; 35(4): 488.     CrossRef
  • Balloon-occluded retrograde transvenous obliteration and simultaneous endoscopic cyanoacrylate injection for treating gastric varices draining through gastrorenal shunts
    Jindong Chu, Zheng Lu, Chunsheng Chi, Wenhui Zhang, Qian Bi, Xuemei Ma, Lijun Shen, Qin Wu, Yanling Wang, Jingjing Han, Xiaoli Yu, Bo Jin
    Arab Journal of Gastroenterology.2023; 24(4): 218.     CrossRef
  • The efficacy and safety of beta-blockers versus cyanoacrylate injection for gastric variceal bleeding
    Yubao Sun, Sheng Li, Feng Li
    Medicine.2021; 100(21): e26039.     CrossRef
  • Endoscopic Cyanoacrylate Glue Injection in Management of Gastric Variceal Bleeding: US Tertiary Care Center Experience
    Subhash Chandra, Adrian Holm, Rami G. El Abiad, Henning Gerke
    Journal of Clinical and Experimental Hepatology.2018; 8(2): 181.     CrossRef
  • Management of gastric varices
    Delphine Weil, Jean-Paul Cervoni, Nadim Fares, Marika Rudler, Christophe Bureau, Aurélie Plessier, Thong Dao, Arnaud Pauwels, Dominique Thabut, Paul Castellani, Frederic Oberti, Nicolas Carbonell, Laure Elkrief, Vincent Di Martino, Thierry Thevenot
    European Journal of Gastroenterology & Hepatology.2016; 28(5): 576.     CrossRef
  • 10,110 View
  • 61 Download
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

The usefulness of transient elastography, acoustic-radiation-force impulse elastography, and real-time elastography for the evaluation of liver fibrosis
Jong Ho Chung, Hyung Su Ahn, Sang Gyune Kim, Yun Nah Lee, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Boo Sung Kim
Clin Mol Hepatol 2013;19(2):156-164.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.156
Background/Aims

Several noninvasive methods have recently been developed for the evaluation of liver fibrosis. The accuracy of transient elastography (TE), acoustic-radiation-force impulse (ARFI) elastography, and real-time elastography (RTE) in predicting liver fibrosis were evaluated.

Methods

Seventy-four patients who had undergone a liver biopsy within the previous 6 months were submitted to evaluation with TE, ARFI, and RTE on the same day.

Results

There were significant correlations between fibrosis stage and liver stiffness measurement (LSM) using the three tested methods: TE, r2=0.272, P=0.0002; ARFI, r2=0.225, P=0.0017; and RTE, r2=0.228, P=0.0015. The areas under the receiver operating characteristic curves (AUROC) for the diagnosis of significant fibrosis (≥F2, Metavir stage) by TE, ARFI, RTE, TE/platelet count (PLT), velocity of shear wave (Vs)/PLT, and elasticity score (Es)/PLT were 0.727, 0.715, 0.507, 0.876, 0.874, and 0.811, respectively. The AUROC for the diagnosis of cirrhosis by TE, ARFI, RTE, TE/PLT, Vs/PLT, and Es/PLT were 0.786, 0.807, 0.767, 0.836, 0.819, and 0.838, respectively. Comparisons of AUROC between all LSMs for predicting significant fibrosis (≥F2) produced the following results: TE vs. RTE, P=0.0069; ARFI vs. RTE, P=0.0277; and TE vs. ARFI, P=0.8836. Applying PLT, the ability of each LSM to predict fibrosis stage significantly increased: TE/PLT vs. TE, P=0.0004; Vs/PLT vs. ARFI, P=0.0022; and Es/PLT vs. RTE, P<0.0001. However, the ability to predict cirrhosis was not enhanced, combining LSM and PLT.

Conclusions

TE and ARFI may be better methods for predicting significant liver fibrosis than RTE. This predictive ability increased significantly when accounting for platelet count. However, all of the measures had comparable efficacies for predicting cirrhosis.

Citations

Citations to this article as recorded by  Crossref logo
  • A comparative study of three ultrasound techniques for liver fibrosis staging
    Qianqian Shen, Jiaqi Zhang, Shangjie Yang, Liping Liu
    European Journal of Gastroenterology & Hepatology.2024; 36(6): 784.     CrossRef
  • ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis
    Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Won Young Tak, Young-Oh Kweon, Soo Young Park, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2023; 21(9): 2278.     CrossRef
  • Diagnostic accuracy of magnetic resonance elastography and point-shear wave elastography for significant hepatic fibrosis screening: Systematic review and meta-analysis
    João Paulo L. Schambeck, Gabriele C. Forte, Luana M. Gonçalves, Guilherme Stuker, João Bruno F. Kotlinski, Giacomo Tramontin, Stephan Altmayer, Guilherme Watte, Bruno Hochhegger, Wan-Long Chuang
    PLOS ONE.2023; 18(2): e0271572.     CrossRef
  • Liver Ultrasound Attenuation
    Ilias Gatos, Petros Drazinos, Spyros Yarmenitis, Ioannis Theotokas, John Koskinas, Emmanouil Koullias, Asimina Mitranou, Emmanuel Manesis, Pavlos S. Zoumpoulis
    Ultrasound Quarterly.2022; 38(2): 124.     CrossRef
  • Evaluating short-term outcomes of the value of sound touch elastography (STE) following the treatment for Budd–Chiari syndrome (BCS): a case series study
    H. Xia, Y.-X. Chen, R. Wang, J. Lu, X.-T. Wang, K. Xu
    Clinical Radiology.2022; 77(8): e606.     CrossRef
  • Comparison of Visual Transient Elastography, Vibration Controlled Transient Elastography, Shear Wave Elastography and Sound Touch Elastography in Chronic liver Disease assessment using liver biopsy as ‘Gold Standard’
    Ilias Gatos, Spyros Yarmenitis, Ioannis Theotokas, John Koskinas, Emmanuel Manesis, Spyros P. Zoumpoulis, Pavlos S. Zoumpoulis
    European Journal of Radiology.2022; 157: 110557.     CrossRef
  • Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C
    Chun-Han Cheng, Chia-Ying Chu, Huan-Lin Chen, I-Tsung Lin, Chia-Hsien Wu, Yuan-Kai Lee, Ping-Jen Hu, Ming-Jong Bair
    Journal of Microbiology, Immunology and Infection.2020; 53(4): 542.     CrossRef
  • Comparison of Sound Touch Elastography, Shear Wave Elastography and Vibration-Controlled Transient Elastography in Chronic Liver Disease Assessment using Liver Biopsy as the “Reference Standard”
    Ilias Gatos, Petros Drazinos, Spyros Yarmenitis, Ioannis Theotokas, Pavlos S. Zoumpoulis
    Ultrasound in Medicine & Biology.2020; 46(4): 959.     CrossRef
  • Deep learning networks on chronic liver disease assessment with fine-tuning of shear wave elastography image sequences
    George C Kagadis, Petros Drazinos, Ilias Gatos, Stavros Tsantis, Panagiotis Papadimitroulas, Stavros Spiliopoulos, Dimitris Karnabatidis, Ioannis Theotokas, Pavlos Zoumpoulis, John D Hazle
    Physics in Medicine & Biology.2020; 65(21): 215027.     CrossRef
  • Evaluation of acoustic radiation force impulse (ARFI) elastography as non-invasive diagnostic tool in living donor liver transplantation
    Hanan Abdelhaleem, Hadeel Gamal Eldeen, Mohammed Mahmoud Nabeel, Reham Abdelmoniem, Wafaa Elakel, Naglaa Zayed, Zeinab Abdellatif, Bahaa Monir, Mohamed Said Abdelaziz, Sherif Mogawer, Mona Elamir, Mostafa Elshazli, Ayman Salah, Adel Hosny, Ayman Yosry
    Abdominal Radiology.2019; 44(2): 464.     CrossRef
  • Liver stiffness measurement by acoustic radiation forced impulse and transient elastography in patients with intrahepatic cholestasis
    Naglaa Zayed, Samar K. Darweesh, Shereef Mousa, Mira Atef, Eman Ramzy, Ayman Yosry
    European Journal of Gastroenterology & Hepatology.2019; 31(4): 520.     CrossRef
  • Temporal stability assessment in shear wave elasticity images validated by deep learning neural network for chronic liver disease fibrosis stage assessment
    Ilias Gatos, Stavros Tsantis, Stavros Spiliopoulos, Dimitris Karnabatidis, Ioannis Theotokas, Pavlos Zoumpoulis, Thanasis Loupas, John D. Hazle, George C. Kagadis
    Medical Physics.2019; 46(5): 2298.     CrossRef
  • Real-Time Elastography: Noninvasive Diagnostic Tool in the Evaluation of Liver Stiffness in Patients with Chronic Viral Hepatitis, Correlation with Histological Examination
    Davide Ippolito, Valentina Schiavone, Cammillo Roberto Talei Franzesi, Alessandra Silvia Casiraghi, Silvia Girolama Drago, Luca Riva, Sandro Sironi
    Digestive Diseases.2018; 36(4): 289.     CrossRef
  • Ultrasound Shear Wave Elastography: Variations of Liver Fibrosis Assessment as a Function of Depth, Force and Distance from Central Axis of the Transducer with a Comparison of Different Systems
    Manish Dhyani, Feixiang Xiang, Qian Li, Luzeng Chen, Changtian Li, Atul K. Bhan, Brian Anthony, Joseph R. Grajo, Anthony E. Samir
    Ultrasound in Medicine & Biology.2018; 44(11): 2209.     CrossRef
  • A Machine-Learning Algorithm Toward Color Analysis for Chronic Liver Disease Classification, Employing Ultrasound Shear Wave Elastography
    Ilias Gatos, Stavros Tsantis, Stavros Spiliopoulos, Dimitris Karnabatidis, Ioannis Theotokas, Pavlos Zoumpoulis, Thanasis Loupas, John D. Hazle, George C. Kagadis
    Ultrasound in Medicine & Biology.2017; 43(9): 1797.     CrossRef
  • Assessment of liver fibrosis in chronic hepatitis: comparison of shear wave elastography and transient elastography
    Shashi B. Paul, Prasenjit Das, Mousumi Mahanta, Vishnubhatla Sreenivas, Saurabh Kedia, Nancy Kalra, Harpreet Kaur, Maneesh Vijayvargiya, Shouriyo Ghosh, Shivanand R. Gamanagatti, Shalimar, Siddhartha Dutta Gupta, Subrat K. Acharya
    Abdominal Radiology.2017; 42(12): 2864.     CrossRef
  • New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis
    Hung-Wei Wang, Cheng-Yuan Peng, Hsueh-Chou Lai, Wen-Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen, Ching-Hsiang Chen, Wei-Fan Hsu, Guan-Tarn Huang
    Scientific Reports.2017;[Epub]     CrossRef
  • Interpretation US Elastography in Chronic Hepatitis B with or without Anti-HBV Therapy
    Cheng-Han Lee, Yung-Liang Wan, Tse-Hwa Hsu, Shiu-Feng Huang, Ming-Chin Yu, Wei-Chen Lee, Po-Hsiang Tsui, Yi-Cheng Chen, Chun-Yen Lin, Dar-In Tai
    Applied Sciences.2017; 7(11): 1164.     CrossRef
  • A new computer aided diagnosis system for evaluation of chronic liver disease with ultrasound shear wave elastography imaging
    Ilias Gatos, Stavros Tsantis, Stavros Spiliopoulos, Dimitris Karnabatidis, Ioannis Theotokas, Pavlos Zoumpoulis, Thanasis Loupas, John D. Hazle, George C. Kagadis
    Medical Physics.2016; 43(3): 1428.     CrossRef
  • Comparison of contrast‐enhanced ultrasonography with virtual touch tissue quantification in the evaluation of focal liver lesions
    Jing‐ping Wu, Rui Shu, Yu‐zhen Zhao, Guo‐lin Ma, Wei Xue, Qi‐jia He, Mei‐na Hao, Yawu Liu
    Journal of Clinical Ultrasound.2016; 44(6): 347.     CrossRef
  • Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison
    Thierry Poynard, Tam Pham, Hugo Perazzo, Mona Munteanu, Elena Luckina, Djamel Elaribi, Yen Ngo, Luminita Bonyhay, Noemie Seurat, Muriel Legroux, An Ngo, Olivier Deckmyn, Dominique Thabut, Vlad Ratziu, Olivier Lucidarme, Seung Up Kim
    PLOS ONE.2016; 11(10): e0163276.     CrossRef
  • Diagnostic Accuracy of Real-Time Tissue Elastography for the Staging of Liver Fibrosis: A Meta-Analysis
    Kunio Kobayashi, Haruhisa Nakao, Takeshi Nishiyama, Yingsong Lin, Shogo Kikuchi, Yuji Kobayashi, Takaya Yamamoto, Norimitsu Ishii, Tomohiko Ohashi, Ken Satoh, Yukiomi Nakade, Kiyoaki Ito, Masashi Yoneda
    European Radiology.2015; 25(1): 230.     CrossRef
  • Evaluation of Liver Stiffness After Radioembolization by Real-Time ShearWave™ Elastography: Preliminary Study
    Ahmet Bas, Cesur Samanci, Fatih Gulsen, Murat Cantasdemir, Levent Kabasakal, Fatih Kantarci, Furuzan Numan
    CardioVascular and Interventional Radiology.2015; 38(4): 957.     CrossRef
  • Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study
    Yeon Seok Seo, Moon Young Kim, Seung Up Kim, Bae Si Hyun, Jae Young Jang, Jin Woo Lee, Jung Il Lee, Sang Jun Suh, Soo Young Park, Hana Park, Eun Uk Jung, Byung Seok Kim, In Hee Kim, Tae Hee Lee, Soon Ho Um, Kwang‐Hyub Han, Sang Gyune Kim, Soon Koo Paik, J
    Liver International.2015; 35(10): 2246.     CrossRef
  • Renal Elasticity Quantification by Acoustic Radiation Force Impulse Applied to the Evaluation of Kidney Diseases
    Marco Zaffanello, Giorgio Piacentini, Costanza Bruno, Milena Brugnara, Vassilios Fanos
    Journal of Investigative Medicine.2015; 63(4): 605.     CrossRef
  • Clinical value of real-time elastography quantitative parameters in evaluating the stage of liver fibrosis and cirrhosis
    LAN GE, BAOMIN SHI, YE SONG, YUAN LI, SHUO WANG, XIUYAN WANG
    Experimental and Therapeutic Medicine.2015; 10(3): 983.     CrossRef
  • Differences in Liver Fibrosis Between Patients With Chronic Hepatitis B and C
    Dar-In Tai, Pei-Kwei Tsay, Wen-Juei Jeng, Chia-Chan Weng, Shiu-Feng Huang, Chien-Hao Huang, Shi-Ming Lin, Cheng-Tang Chiu, Wei-Ting Chen, Yung-Liang Wan
    Journal of Ultrasound in Medicine.2015; 34(5): 813.     CrossRef
  • Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease
    Marianthi Papagianni
    World Journal of Hepatology.2015; 7(4): 638.     CrossRef
  • Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis
    A. J. Czaja
    Alimentary Pharmacology & Therapeutics.2014; 39(4): 385.     CrossRef
  • Performance of Real-Time Elastography for the Staging of Hepatic Fibrosis: A Meta-Analysis
    Huisuo Hong, Jia Li, Yin Jin, Qiao Li, Weimin Li, Jiansheng Wu, Zhiming Huang, Seung Up Kim
    PLoS ONE.2014; 9(12): e115702.     CrossRef
  • 12,851 View
  • 128 Download
  • Crossref

Review

Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions
Jae Young Jang, Moon Young Kim, Soung Won Jeong, Tae Yeob Kim, Seung Up Kim, Sae Hwan Lee, Ki Tae Suk, Soo Young Park, Hyun Young Woo, Sang Gyune Kim, Jeong Heo, Soon Koo Baik, Hong Soo Kim, Won Young Tak
Korean J Hepatol 2013;19(1):1-16.
Published online March 25, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.1.1

The application of ultrasound contrast agents (UCAs) is considered essential when evaluating focal liver lesions (FLLs) using ultrasonography (US). Microbubble UCAs are easy to use and robust; their use poses no risk of nephrotoxicity and requires no ionizing radiation. The unique features of contrast enhanced US (CEUS) are not only noninvasiveness but also real-time assessing of liver perfusion throughout the vascular phases. The later feature has led to dramatic improvement in the diagnostic accuracy of US for detection and characterization of FLLs as well as the guidance to therapeutic procedures and evaluation of response to treatment. This article describes the current consensus and guidelines for the use of UCAs for the FLLs that are commonly encountered in US. After a brief description of the bases of different CEUS techniques, contrast-enhancement patterns of different types of benign and malignant FLLs and other clinical applications are described and discussed on the basis of our experience and the literature data.

Citations

Citations to this article as recorded by  Crossref logo
  • Differentiating between hepatocellular carcinoma and its mimickers using contrast-enhanced ultrasound with perflubutane microbubbles
    Yasunori Minami, Katsutoshi Sugimoto, Hidekatus Kuroda, Naohisa Kamiyama, Chikara Ogawa, Masatoshi Kudo
    Expert Review of Medical Devices.2025; 22(8): 817.     CrossRef
  • Diagnosis and Management of Benign Liver Tumors
    Yeonjung Ha
    The Korean Journal of Gastroenterology.2025; 85(3): 314.     CrossRef
  • Operative Procedures for Ultrasound Assessment of Extracranial Artery Disease: A Narrative Review by the Italian Society for Vascular Investigation (SIDV)
    Luca Costanzo, Giacomo Failla, Leonardo Aluigi, Tiziana Anna Baroncelli, Chiara Bua, Sergio De Marchi, Elia Diaco, Federico Di Paola, Francesco Lorenzo Di Pino, Ferdinando Mannello, Ombretta Martinelli, Chiara Mascoli, Anastasia Maria Pedi, Ivan Privitera
    Journal of Clinical Medicine.2025; 14(19): 7050.     CrossRef
  • Addition of contrast in ultrasound screening for hepatocellular carcinoma
    Kathryn McGillen, Nabeal Aljabban, Robert Wu, Benjamin Shin, Ian Schreibman, Franklin Luke, James Birkholz
    Research in Diagnostic and Interventional Imaging.2024; 9: 100039.     CrossRef
  • Development and Validation of a Nomogram to Predict the Recurrence of HCC Patients Undergoing CECT After Ablation
    Wenying Qiao, Zibo Fan, Qi Wang, Ronghua Jin, Caixia Hu
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 65.     CrossRef
  • The added value of color parameter imaging for the evaluation of focal liver lesions with “homogenous hyperenhancement and no wash out” on contrast enhanced ultrasound
    Zi-Nan Liang, Song Wang, Wei Yang, Hong Wang, Kun Zhao, Xiu-Mei Bai, Zhong-Yi Zhang, Wei Wu, Kun Yan
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Hepatic Hemangioma: Review of Imaging and Therapeutic Strategies
    Arkadiusz Kacała, Mateusz Dorochowicz, Iwona Matus, Michał Puła, Adrian Korbecki, Michał Sobański, Jagoda Jacków-Nowicka, Dariusz Patrzałek, Dariusz Janczak, Maciej Guziński
    Medicina.2024; 60(3): 449.     CrossRef
  • Principle of contrast-enhanced ultrasonography
    Yoshitaka Mine, Etsuo Takada, Katsutoshi Sugimoto, Fuminori Moriyasu
    Journal of Medical Ultrasonics.2024; 51(4): 567.     CrossRef
  • Ultrasomics in liver cancer: Developing a radiomics model for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma using contrast-enhanced ultrasound
    Li-Ya Su, Ming Xu, Yan-Lin Chen, Man-Xia Lin, Xiao-Yan Xie
    World Journal of Radiology.2024; 16(7): 247.     CrossRef
  • The role of CEUS as problem-solving technique when abdominal CT or MRI are inconclusive
    Antonino Andrea Blandino, Davide Giangrande, Roberto Cannella, Tommaso Vincenzo Bartolotta
    Journal of Medical Imaging and Interventional Radiology.2024;[Epub]     CrossRef
  • Perfusion Patterns of Peripheral Pulmonary Metastasis Using Contrast-Enhanced Ultrasound (CEUS) and Their Correlation with Immunohistochemically Detected Vascularization Pattern
    Johannes Kroenig, Christian Görg, Helmut Prosch, Lara Von Schumann, Christina C. Westhoff, Amjad Alhyari, Felix R. M. Koenig, Hajo Findeisen, Ehsan Safai Zadeh
    Cancers.2024; 16(19): 3365.     CrossRef
  • Contrast-Enhanced Ultrasound with Optimized Aperture Patterns and Bubble Segmentation Based on Echo Phase
    Ting-Yu Lai, Michalakis A. Averkiou
    Ultrasound in Medicine & Biology.2023; 49(1): 186.     CrossRef
  • Diagnostic performance of contrast‐enhanced ultrasound in diagnosing hepatic artery occlusion after liver transplantation: A systematic review and meta‐analysis
    Busara Songtanin, Kevin Brittan, Sebastian Sanchez, Michelle Le, Cynthia Schmidt, Thammasin Ingviya, Wuttiporn Manatsathit
    Clinical Transplantation.2023;[Epub]     CrossRef
  • Assessment of focal liver lesions in non-cirrhotic liver – expert opinion statement by the Swiss Association for the Study of the Liver and the Swiss Society of Gastroenterology
    Mikael Sawatzki, Daniela B. Husarik, David Semela
    Swiss Medical Weekly.2023; 153(9): 40099.     CrossRef
  • Establishment and Validation of the LI-RADS Morphologic Type II Hepatocellular Carcinoma Early Recurrence Risk Scoring System
    Yajuan Sun, Can Yu, Xinxin Wang, Rui Yang, ZhiPeng Ding, Yang Zhou
    Journal of Gastrointestinal Surgery.2023; 27(12): 2787.     CrossRef
  • High Frame Rate Contrast-enhanced Ultrasound Helps Differentiate Malignant and Benign Focal Liver Lesions
    Xiang Fei, Peng Han, Bo Jiang, Lianhua Zhu, Wenshuo Tian, Maodong Sang, Xirui Zhang, Yaqiong Zhu, Yukun Luo
    Journal of Clinical and Translational Hepatology.2022; 10(1): 26.     CrossRef
  • Computer-Aided Color Parameter Imaging of Contrast-Enhanced Ultrasound Evaluates Hepatocellular Carcinoma Hemodynamic Features and Predicts Radiofrequency Ablation Outcome
    Hong Wang, Wen Guo, Wei Yang, Gang Liu, Kun Cao, Yu Sun, Zi-Nan Liang, Xiu-Mei Bai, Song Wang, Wei Wu, Kun Yan, S. Nahum Goldberg
    Ultrasound in Medicine & Biology.2022; 48(8): 1555.     CrossRef
  • Diagnostic accuracy of hepatic vein arrival time performed with contrast-enhanced ultrasonography for HCV liver cirrhosis
    Nahed A. Makhlouf, Ehab F. Moustafa, Sahar M. Hassany
    Arab Journal of Gastroenterology.2022; 23(3): 195.     CrossRef
  • Algorithm‐based approach to focal liver lesions in contrast‐enhanced ultrasound
    Kheng Song Leow, Christine Ying Kwok, Hsien Min Low, Rahul Lohan, Tze Chwan Lim, Su Chong Albert Low, Cher Heng Tan
    Australasian Journal of Ultrasound in Medicine.2022; 25(3): 142.     CrossRef
  • Application of Contrast-Enhanced Ultrasonography with Sonazoid for Focal Liver Lesions
    颖 高
    Advances in Clinical Medicine.2022; 12(10): 9470.     CrossRef
  • Streptococcus pyogenes infection of a mediastinal cyst after endoscopic ultrasound-guided fine-needle aspiration
    Shutong Zhou, Hongtao Wei, Huihong Zhai
    Heliyon.2022; 8(12): e11900.     CrossRef
  • Investigation of the Phase of Nonlinear Echoes From Microbubbles During Amplitude Modulation
    Sara B. Keller, Ting-Yu Lai, Lance De Koninck, Michalakis A. Averkiou
    IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.2022; 69(3): 1032.     CrossRef
  • Informativeness of methods of radiation diagnostics in the detection of liver hemangiomas
    V.N. Najafova
    Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini.2021; 2021(2b): 108.     CrossRef
  • Application of new ultrasound techniques for focal liver lesions
    Feiqian WANG, Kazushi NUMATA, Hiromi NIHONMATSU, Masahiro OKADA, Shin MAEDA
    Choonpa Igaku.2021; 48(6): 317.     CrossRef
  • Cavitation Therapy Monitoring of Commercial Microbubbles With a Clinical Scanner
    Sara B. Keller, Paul S. Sheeran, Michalakis A. Averkiou
    IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.2021; 68(4): 1144.     CrossRef
  • A novel method to determine hepatic segments using Sonazoid, an ultrasound contrast agent
    Taehyuk Ham, Joo Hee Jeon, Younghoon Roh, Sungwook Lee, Sangyoon Lee, Heejin Kwon, Jin Han Cho
    Ultrasonography.2020; 39(1): 94.     CrossRef
  • Application of new ultrasound techniques for focal liver lesions
    Feiqian Wang, Kazushi Numata, Hiromi Nihonmatsu, Masahiro Okada, Shin Maeda
    Journal of Medical Ultrasonics.2020; 47(2): 215.     CrossRef
  • Differentiation of atypical hepatic hemangioma from liver metastases: Diagnostic performance of a novel type of color contrast enhanced ultrasound
    Xiao-Feng Wu, Xiu-Mei Bai, Wei Yang, Yu Sun, Hong Wang, Wei Wu, Min-Hua Chen, Kun Yan
    World Journal of Gastroenterology.2020; 26(9): 960.     CrossRef
  • The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid
    Jae Young Lee, Yasunori Minami, Byung Ihn Choi, Won Jae Lee, Yi-Hong Chou, Woo Kyoung Jeong, Mi-Suk Park, Nobuki Kudo, Min Woo Lee, Ken Kamata, Hiroko Iijima, So Yeon Kim, Kazushi Numata, Katsutoshi Sugimoto, Hitoshi Maruyama, Yasukiyo Sumino, Chikara Oga
    Ultrasonography.2020; 39(3): 191.     CrossRef
  • A pilot trial to evaluate the clinical usefulness of contrast-enhanced ultrasound in predicting renal outcomes in patients with acute kidney injury
    Hye Eun Yoon, Da Won Kim, Dongryul Kim, Yaeni Kim, Seok Joon Shin, Yu Ri Shin, Tatsuo Shimosawa
    PLOS ONE.2020; 15(6): e0235130.     CrossRef
  • Contrast-Enhanced Ultrasonography for Screening and Diagnosis of Hepatocellular Carcinoma: A Case Series and Review of the Literature
    Kathryn L. McGillen, Syeda Zaidi, Amer Ahmed, Shantell Harter, Nelson S. Yee
    Medicines.2020; 7(9): 51.     CrossRef
  • Accuracy of contrast-enhanced ultrasound liver imaging reporting and data system: a systematic review and meta-analysis
    Jung Hee Son, Sang Hyun Choi, So Yeon Kim, So Jung Lee, Seong Ho Park, Kyung Won Kim, Hyung Jin Won, Yong Moon Shin, Pyo-Nyun Kim
    Hepatology International.2020; 14(6): 1104.     CrossRef
  • Intraoperative Imaging Techniques to Visualize Hepatic (Micro)Perfusion: An Overview
    Zühre Uz, Lucinda Shen, Dan M.J. Milstein, Krijn P. van Lienden, Rutger-Jan Swijnenburg, Can Ince, Thomas M. van Gulik
    European Surgical Research.2020; 61(1): 2.     CrossRef
  • Dynamic Contrast-Enhanced Ultrasound of Gastric Cancer: Correlation with Perfusion CT and Histopathology
    Ijin Joo, Se Hyung Kim, Dong Ho Lee, Joon Koo Han
    Korean Journal of Radiology.2019; 20(5): 781.     CrossRef
  • Occurrence, diagnosis and management of hepatic fibrosis and cirrhosis: An updated literature review
    J Qiao
    Archives of Hepatitis Research.2019; 5(1): 022.     CrossRef
  • Focal Liver Lesions: Computer-aided Diagnosis by Using Contrast-enhanced US Cine Recordings
    Casey N. Ta, Yuko Kono, Mohammad Eghtedari, Young Taik Oh, Michelle L. Robbin, Richard G. Barr, Andrew C. Kummel, Robert F. Mattrey
    Radiology.2018; 286(3): 1062.     CrossRef
  • Contrast-Enhanced Ultrasound of the Liver: Optimizing Technique and Clinical Applications
    Emily H. T. Pang, Andy Chan, Stephen G. Ho, Alison C. Harris
    American Journal of Roentgenology.2018; 210(2): 320.     CrossRef
  • Contrast‐Enhanced Ultrasonography Versus Contrast‐Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Meta‐analysis
    Junlin Zhong, Zhongzhen Su, Yanling Zhang, Hui Zhang, Peijie Lin, Xixiang Tang, Rongqin Zheng
    Journal of Ultrasound in Medicine.2018; 37(8): 1881.     CrossRef
  • Contrast-Enhanced Ultrasonography in Sclerotherapy for Ovarian Endometrial Cyst
    Xiao-Hui Shao, Xiao-Qiu Dong, De-Jiao Kong, Li-Wei Zhang, Lu-Lu Wang, Si-Ming Wang
    Ultrasound in Medicine & Biology.2018; 44(8): 1828.     CrossRef
  • Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: Comparison of contrast-enhanced ultrasound with multiphase computed tomography
    S.B. Paul, E. Dhamija, S.R. Gamanagatti, V. Sreenivas, D.P. Yadav, S. Jain, Shalimar, S.K. Acharya
    Diagnostic and Interventional Imaging.2017; 98(3): 253.     CrossRef
  • Added Value of Contrast-Enhanced Ultrasound on Biopsies of Focal Hepatic Lesions Invisible on Fusion Imaging Guidance
    Tae Wook Kang, Min Woo Lee, Kyoung Doo Song, Mimi Kim, Seung Soo Kim, Seong Hyun Kim, Sang Yun Ha
    Korean Journal of Radiology.2017; 18(1): 152.     CrossRef
  • Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis
    Gaeun Kim, Kwang Yong Shim, Soon Koo Baik
    Gut and Liver.2017; 11(1): 93.     CrossRef
  • Diagnosis and management of liver masses in pregnancy
    James Milburn, Mairead Black, Irfan Ahmed, Lindsay McLeman, Jack Straiton, Peter Danielian
    The Obstetrician & Gynaecologist.2016; 18(1): 43.     CrossRef
  • Ecografía hepática: lesiones focales y enfermedades difusas
    A. Segura Grau, I. Valero López, N. Díaz Rodríguez, J.M. Segura Cabral
    SEMERGEN - Medicina de Familia.2016; 42(5): 307.     CrossRef
  • Contrast agents in diagnostic imaging: Present and future
    Luca Caschera, Angelo Lazzara, Lorenzo Piergallini, Domenico Ricci, Bruno Tuscano, Angelo Vanzulli
    Pharmacological Research.2016; 110: 65.     CrossRef
  • Vascular phases in imaging and their role in focal liver lesions assessment
    Liliana Chiorean, Cosmin Caraiani, Maija Radziņa, Maciej Jedrzejczyk, Dagmar Schreiber-Dietrich, Christoph F. Dietrich
    Clinical Hemorheology and Microcirculation.2016; 62(4): 299.     CrossRef
  • Contrast-Enhanced Ultrasound of Focal Liver Lesions
    Nitin Chaubal, Mukund Joshi, Anupam Bam, Rajas Chaubal
    Seminars in Roentgenology.2016; 51(4): 334.     CrossRef
  • Optimal injection rate of ultrasound contrast agent for evaluation of focal liver lesions using an automatic power injector: a pilot study
    Katsutoshi Sugimoto, Fuminori Moriyasu, Hirohito Takeuchi, Mayumi Kojima, Saori Ogawa, Takatomo Sano, Yoshihiro Furuichi, Yoshiyuki Kobayashi, Ikuo Nakamura
    SpringerPlus.2016;[Epub]     CrossRef
  • Contrast Enhanced Ultrasound for the Differentiation of Hepatic Mass
    Jae Young Jang
    Clinical Ultrasound.2016; 1(2): 71.     CrossRef
  • The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study
    Youn Zoo Cho, So Yeon Park, Eun Hee Choi, Soon Koo Baik, Sang Ok Kwon, Young Ju Kim, Seung Hwan Cha, Moon Young Kim
    Clinical and Molecular Hepatology.2015; 21(2): 165.     CrossRef
  • Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma
    Kil Hyo Park, Soon Ha Kwon, Yong Sub Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Yong Jae Kim
    Clinical and Molecular Hepatology.2015; 21(2): 158.     CrossRef
  • Focal masses in a non-cirrhotic liver: The additional benefit of CEUS over baseline imaging
    L. Chiorean, V. Cantisani, C. Jenssen, P.S. Sidhu, U. Baum, C.F. Dietrich
    European Journal of Radiology.2015; 84(9): 1636.     CrossRef
  • Evaluation of the diagnostic accuracy of CEUS in children with benign and malignant liver lesions and portal vein anomalies
    K. Pschierer, D. Grothues, J. Rennert, N. Platz Batista da Silva, A.G. Schreyer, M. Melter, C. Stroszczysnski, E.M. Jung
    Clinical Hemorheology and Microcirculation.2015; 61(2): 333.     CrossRef
  • Contrast-Enhanced Ultrasound in the Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Controversy over the ASSLD Guideline
    Le-Hang Guo, Hui-Xiong Xu
    BioMed Research International.2015; 2015: 1.     CrossRef
  • CONSUMER PREFERENCES FOR SCANNING MODALITY TO DIAGNOSE FOCAL LIVER LESIONS
    Jennifer Whitty, Alexandra Filby, Adam B Smith, Louise M Carr
    International Journal of Technology Assessment in Health Care.2015; 31(1-2): 27.     CrossRef
  • Inertial cavitation threshold of nested microbubbles
    N. Wallace, S. Dicker, Peter Lewin, S.P. Wrenn
    Ultrasonics.2015; 58: 67.     CrossRef
  • Radiofrequency ablation of very-early-stage hepatocellular carcinoma inconspicuous on fusion imaging with B-mode US: value of fusion imaging with contrast-enhanced US
    Ji Hye Min, Hyo Keun Lim, Sanghyeok Lim, Tae Wook Kang, Kyoung Doo Song, Seo-youn Choi, Hyunchul Rhim, Min Woo Lee
    Clinical and Molecular Hepatology.2014; 20(1): 61.     CrossRef
  • Influence of nesting shell size on brightness longevity and resistance to ultrasound-induced dissolution during enhanced B-mode contrast imaging
    N. Wallace, S. Dicker, P. Lewin, S.P. Wrenn
    Ultrasonics.2014; 54(8): 2099.     CrossRef
  • Continuous Dynamic Registration of Microvascularization of Liver Tumors with Contrast-Enhanced Ultrasound
    Lukas Philipp Beyer, Benedikt Pregler, Isabel Wiesinger, Christian Stroszczynski, Philipp Wiggermann, Ernst-Michael Jung
    Radiology Research and Practice.2014; 2014: 1.     CrossRef
  • Efficacy of contrast grey scale ultrasound in characterization of hepatic focal lesions
    C.G. Muralidharan
    Medical Journal Armed Forces India.2014; 70(4): 397.     CrossRef
  • Clinically Useful Diagnostic Tool of Contrast Enhanced Ultrasonography for Focal Liver Masses: Comparison to Computed Tomography and Magnetic Resonance Imaging
    Sung Woo Ryu, Gene Hyun Bok, Jae Young Jang, Soung Won Jeong, Nam Seok Ham, Ji Hye Kim, Eui Ju Park, Jin Nyoung Kim, Woong Cheul Lee, Kwang Yeun Shim, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim
    Gut and Liver.2014; 8(3): 292.     CrossRef
  • Alcohol and hepatocellular carcinoma: A review and a point of view
    Gianni Testino, Silvia Leone, Paolo Borro
    World Journal of Gastroenterology.2014; 20(43): 15943.     CrossRef
  • Contrast‐enhanced ultrasound for focal liver lesions. Is it necessary an hepatologist expert in ultrasound techniques in the third millennium?
    Paolo Borro, Gianni Testino
    Liver International.2013; 33(10): 1609.     CrossRef
  • 21,833 View
  • 346 Download
  • Crossref

Original Articles

Liver fibrosis, cirrhosis, and portal hypertension

Relationship between the hepatic venous pressure gradient and first variceal hemorrhage in patients with cirrhosis: a multicenter retrospective study in Korea
Jin Nyoung Kim, Kyoung Min Sohn, Moon Young Kim, Ki Tae Suk, Soung Won Jeong, Ho Eun Jung, Sae Hwan Lee, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Soon Koo Baik, Hong Soo Kim, Dong Joon Kim, Boo Sung Kim
Korean J Hepatol 2012;18(4):391-396.
Published online December 21, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.4.391
Background/Aims

Variceal hemorrhage is one of the major complications of cirrhosis and is associated with significant mortality and morbidity. The development of gastroesophageal varices and variceal hemorrhage is the most direct consequence of portal hypertension. Correlations between the hepatic venous pressure gradient (HVPG) and first variceal hemorrhage were examined.

Methods

Patients with cirrhosis who underwent HVPG measurement between July 2009 and September 2010 were enrolled (n=535). All patients underwent esophagogastroduodenoscopy to enable the evaluation of gastroesophageal varices.

Results

The HVPG for all patients was 16.46±7.05 mmHg (mean±SD), and was significantly higher among those with first variceal hemorrhage than in those without it. The HVPG was significantly correlated with both Child-Turcotte-Pugh (r=0.488, P<0.001) and Model for End-stage Liver Disease (r=0.478, P<0.001) scores. An HVPG value of 11 mmHg was predictive of first variceal hemorrhage with a sensitivity of 92.4% and a specificity of 27.7%.

Conclusions

The HVPG was higher in patients with first variceal hemorrhage than in those without it.

Citations

Citations to this article as recorded by  Crossref logo
  • Hepatic Venous Pressure Gradient Measurement and its Limitation
    Nadera Altork, Spyridon Peppas, Atoosa Rabiee
    Current Hepatology Reports.2025;[Epub]     CrossRef
  • The independent prognostic value of perioperative hepatic venous pressure gradient measurements in patients with portal hypertension who underwent laparoscopic splenectomy plus esophagogastric devascularization
    Ming Zhang, Dong Wang, Xiao Chen, Defeng Liang, Tao Yang, Yanlong Cao, Bo Huang, Jianguo Lu, Jikai Yin
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Accuracy of liver and spleen stiffness on magnetic resonance elastography for detecting portal hypertension: a systematic review and meta-analysis
    Ranjit Singh, Mitchell P. Wilson, Prayash Katlariwala, Mohammad H. Murad, Matthew D.F. McInnes, Gavin Low
    European Journal of Gastroenterology & Hepatology.2021; 32(2): 237.     CrossRef
  • Development and validation of prognostic model to predict mortality among cirrhotic patients with acute variceal bleeding: A retrospective study
    Sakkarin Chirapongsathorn, Kuntapon Akkarachinores, Amnart Chaiprasert
    JGH Open.2021; 5(6): 658.     CrossRef
  • Invasive measurement of portal hypertension in the hemodynamics laboratory as an important element of qualification for the treatment of esophageal varices: A single-center experience
    Krystian Bojko, Adam Kern, Tomasz Arłukowicz, Leszek Gromadziński, Jerzy Górny, Dariusz Onichimowski, Rakesh Jalali, Damian Kabziński, Artur Zarzecki, Jacek Bil
    Polish Annals of Medicine.2021;[Epub]     CrossRef
  • Long-term efficacy of subtotal splenectomy due to portal hypertension in cirrhotic patients
    Haibo Chu, Wei Han, Lei Wang, Yongbo Xu, Fengguo Jian, Weihua Zhang, Tao Wang, Jianhua Zhao
    BMC Surgery.2015;[Epub]     CrossRef
  • Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement
    Ki Tae Suk
    World Journal of Hepatology.2015; 7(3): 607.     CrossRef
  • Hepatic venous pressure gradient: clinical use in chronic liver disease
    Ki Tae Suk
    Clinical and Molecular Hepatology.2014; 20(1): 6.     CrossRef
  • Relationship between Tetrahydrobiopterin and Portal Hypertension in Patients with Chronic Liver Disease
    Won Ki Hong, Kwang Yong Shim, Soon Koo Baik, Moon Young Kim, Mee Yon Cho, Yoon Ok Jang, Young Shik Park, Jin Han, Gaeun Kim, Youn Zoo Cho, Hye Won Hwang, Jin Hyung Lee, Myeong Hun Chae, Sang Ok Kwon
    Journal of Korean Medical Science.2014; 29(3): 392.     CrossRef
  • The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data
    Won Ki Hong, Moon Young Kim, Soon Koo Baik, Seung Yong Shin, Jung Min Kim, Yong Seok Kang, Yoo Li Lim, Young Ju Kim, Youn Zoo Cho, Hye Won Hwang, Jin Hyung Lee, Myeong Hun Chae, Hyoun A Kim, Hye Won Kang, Sang Ok Kwon
    Clinical and Molecular Hepatology.2013; 19(4): 370.     CrossRef
  • Characteristics of alcoholic liver disease and predictive factors for mortality of patients with alcoholic cirrhosis
    Yan-Di Xie, Bo Feng, Yan Gao, Lai Wei
    Hepatobiliary & Pancreatic Diseases International.2013; 12(6): 594.     CrossRef
  • 12,016 View
  • 81 Download
  • Crossref

Autoimmune liver disease

Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score
Ho Eun Jung, Jae Young Jang, Soung Won Jeong, Jin Nyoung Kim, Hee Yoon Jang, Yun Ju Cho, Sung Ae Woo, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim
Korean J Hepatol 2012;18(4):375-382.
Published online December 21, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.4.375
Background/Aims

Primary biliary cirrhosis (PBC) is a slowly progressing autoimmune disease of the liver that is characterized by portal inflammation and immune-mediated destruction of the intrahepatic bile ducts. Serum total bilirubin is one of the various prognostic factors that have been proposed. A recent study found that PBC with accompanying autoimmune hepatitis (AIH) carries a negative prognosis. This study examined the clinical characteristics of PBC and analyzed the factors that affect its prognosis.

Methods

Patients diagnosed with PBC between January 1998 and December 2010 based on clinical and histopathological findings were compiled and analyzed retrospectively.

Results

Among 27 patients, 24 (1 male and 23 females, ages 50.0±9.3 years) were followed up. The follow-up period was 8.6±0.9 years. Of the 24 patients, 9 patients progressed to liver cirrhosis (LC). Comparison between patients who did and did not progress to LC revealed statistically significant differences in the patients' serum total bilirubin (2.7±1.8 vs. 0.8±0.4, P=0.012), the Mayo risk score (5.1±0.7 vs. 3.9±0.6, P=0.001), the revised IAHG (International Autoimmune Hepatitis Group) score (9.2±2.3 vs. 5.4±3.0, P=0.004) and frequency of AIH overlap (5/9 [55.6%] vs. 0/15 [0%], P=0.001) at the time of diagnosis.

Conclusions

We propose that serum total bilirubin, the Mayo risk score, and the revised IAHG score at the time of diagnosis are helpful for predicting PBC prognosis. In particular, since all of the patients with accompanying AIH progressed to LC, the presence of overlap syndrome at the time of diagnosis is helpful for predicting PBC prognosis and providing an adequate treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Pruritus, Fatigue, Osteoporosis and Dyslipoproteinemia in Pbc Patients: A Clinician’s Perspective
    Sylvia Drazilova, Tomas Koky, Marian Macej, Martin Janicko, Dagmar Simkova, Ariunzaya Tsedendamba, Slavomira Komarova, Peter Jarcuska
    Gastroenterology Insights.2024; 15(2): 419.     CrossRef
  • Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
    Albert Parés, Mitchell Shiffman, Victor Vargas, Pietro Invernizzi, Elizabeth S. Malecha, Alexander Liberman, Leigh MacConell, Gideon Hirschfield
    Liver International.2020; 40(5): 1121.     CrossRef
  • Hepatic ADC map as an adjunct to conventional abdominal MRI to evaluate hepatic fibrotic and clinical cirrhotic severity in biliary atresia patients
    Steven Shinn-Forng Peng, Yung-Ming Jeng, Wen-Ming Hsu, Justin Cheng-Ta Yang, Ming-Chih Ho
    European Radiology.2015; 25(10): 2992.     CrossRef
  • Overlap syndromes of autoimmune hepatitis: diagnosis and treatment
    O. Aguilar-Nájera, J.A. Velasco-Zamora, A. Torre
    Revista de Gastroenterología de México (English Edition).2015; 80(2): 150.     CrossRef
  • Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes
    Yoonsang Park, Yuri Cho, Eun Ju Cho, Yoon Jun Kim
    Clinical and Molecular Hepatology.2015; 21(2): 150.     CrossRef
  • Diagnóstico y tratamiento de los síndromes de sobreposición de hepatitis autoinmune
    O. Aguilar-Nájera, J.A. Velasco-Zamora, A. Torre
    Revista de Gastroenterología de México.2015; 80(2): 150.     CrossRef
  • Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis
    Vasiliy Ivanovich Reshetnyak
    World Journal of Gastroenterology.2015; 21(25): 7683.     CrossRef
  • Primary Biliary Cirrhosis and Primary Sjögren's Syndrome: Insights for the Stomatologist
    Liliane Lins, Raymundo Paraná, Silvia Regina Almeida Reis, Antônio Fernando Pereira Falcão
    Case Reports in Gastroenterology.2014; 8(2): 251.     CrossRef
  • 14,764 View
  • 70 Download
  • Crossref

Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma
Soon Ha Kwon, Soung Won Jeong, Jae Young Jang, Ji Eun Lee, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, So-Young Jin
Korean J Hepatol 2012;18(3):287-294.
Published online September 25, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.3.287
Background/Aims

Cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) are up-regulated in hepatocellular carcinoma (HCC). To investigate the levels of COX-2 and VEGF expression in chronic hepatitis (CH), cirrhosis, and HCC.

Methods

The immunohistochemical expressions of COX-2 and VEGF were evaluated in tissues from patients with CH (n=95), cirrhosis (n=38), low-grade HCC (LG-HCC; n=6), and high-grade HCC (HG-HCC; n=29).

Results

The COX-2 expression scores in CH, cirrhosis, LG-HCC, and HG-HCC were 3.3±1.9 (mean±SD), 4.2±1.7, 5.5±1.0, and 3.4±2.4, respectively (CH vs. cirrhosis, P=0.016; CH vs. LG-HCC, P=0.008; LG-HCC vs. HG-HCC, P=0.004), and the corresponding VEGF expression scores were 0.9±0.8, 1.5±0.7, 1.8±0.9, and 1.6±1.1 (CH vs. cirrhosis, P<0.001; CH vs. LG-HCC, P=0.011; LG-HCC vs. HG-HCC, P=0.075). Both factors were correlated with the fibrosis stage in CH and cirrhosis (COX-2: r=0.427, P<0.001; VEGF: r=0.491, P<0.001). There was a significant correlation between COX-2 and VEGF in all of the tissue samples (r=0.648, P<0.001), and between high COX-2 and VEGF expression scores and survival (COX-2: P=0.001; VEGF: P<0.001).

Conclusions

The expressions of both COX-2 and VEGF are significantly higher in cirrhosis and LG-HCC than in CH. High COX-2 and high VEGF expressions are associated with a high survival rate.

Citations

Citations to this article as recorded by  Crossref logo
  • Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features
    Xinhua Zou, Qingyu Xu, Ran You, Guowen Yin
    Cancer Medicine.2023; 12(10): 11315.     CrossRef
  • Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma
    Hui Li
    Digestive and Liver Disease.2022; 54(5): 598.     CrossRef
  • Altered expression of COX-2 and TNF-a in patients with hepatocellular carcinoma
    Andressa de-Freitas-Alves, Vanessa Dido-Baldissera, Eduardo Cremonese-Filippi-Chiela, Carlos Thadeu Schmidt-Cerski, Paulo Roberto Ott-Fontes, Marilda da-Cruz-Fernandes, Marilene Porawski, Márcia Giovenardi
    Revista Española de Enfermedades Digestivas.2019;[Epub]     CrossRef
  • HBx combined with AFB1 triggers hepatic steatosis via COX‐2‐mediated necrosome formation and mitochondrial dynamics disorder
    Yuan‐Yuan Chen, Yi Lin, Pei‐Yu Han, Shan Jiang, Lin Che, Cheng‐Yong He, Yu‐Chun Lin, Zhong‐Ning Lin
    Journal of Cellular and Molecular Medicine.2019; 23(9): 5920.     CrossRef
  • Fluorescence imaging of hepatocellular carcinoma with a specific probe of COX-2
    Haibo Wang, Chengyong Dong, Keqiu Jiang, Shuangzhe Zhang, Fei Long, Rixin Zhang, Deguang Sun, Rui Liang, Zhenming Gao, Shujuan Shao, Liming Wang
    RSC Advances.2018; 8(2): 994.     CrossRef
  • Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights
    Thomas Greuter, Vijay H. Shah
    Journal of Gastroenterology.2016; 51(6): 511.     CrossRef
  • Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features
    Osmar Damasceno Ribeiro, Nathalie Henriques Silva Canedo, Vera Lucia Pannain
    Clinics.2016; 71(11): 639.     CrossRef
  • Liver sinusoidal endothelial cells in hepatic fibrosis
    Laurie D. DeLeve
    Hepatology.2015; 61(5): 1740.     CrossRef
  • Constitutive activation of AMPK α1 in vascular endothelium promotes high‐fat diet‐induced fatty liver injury: role of COX‐2 induction
    Yan Liang, Bosheng Huang, Erfei Song, Bo Bai, Yu Wang
    British Journal of Pharmacology.2014; 171(2): 498.     CrossRef
  • Glycyrrhetinic Acid Suppressed NF-κB Activation in TNF-α-Induced Hepatocytes
    Hong-Jhang Chen, Shih-Pei Kang, I-Jung Lee, Yun-Lian Lin
    Journal of Agricultural and Food Chemistry.2014; 62(3): 618.     CrossRef
  • Meloxicam Executes Its Antitumor Effects against Hepatocellular Carcinoma in COX-2- Dependent and -Independent Pathways
    Xiaofeng Dong, Rui Li, Peng Xiu, Xuesong Dong, Zongzhen Xu, Bo Zhai, Feng Liu, Hongchi Jiang, Xueying Sun, Jie Li, Haiquan Qiao, Diego Calvisi
    PLoS ONE.2014; 9(3): e92864.     CrossRef
  • Epithelial VEGF signaling is required in the mouse liver for proper sinusoid endothelial cell identity and hepatocyte zonation in vivo
    Teagan J. Walter, Ashley E. Cast, Kari A. Huppert, Stacey S. Huppert
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2014; 306(10): G849.     CrossRef
  • 10,219 View
  • 92 Download
  • Crossref

Drug induced liver injury

The clinical features of drug-induced liver injury observed through liver biopsy: focus on relevancy to autoimmune hepatitis
Hye Young Ju, Jae Young Jang, Soung Won Jeong, Sung Ae Woo, Min Gyu Kong, Hee Yoon Jang, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, So Young Jin, Hong Soo Kim, Boo Sung Kim
Korean J Hepatol 2012;18(2):213-218.
Published online June 26, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.2.213
Background/Aims

Accurate diagnosis of drug-induced liver injury (DILI) is difficult without considering the possibility of underlying diseases, especially autoimmune hepatitis (AIH). We investigated the clinical patterns in patients with a history of medication, liver-function abnormalities, and in whom liver biopsy was conducted, focusing on accompaniment by AIH.

Methods

The clinical, serologic, and histologic findings of 29 patients were compared and analyzed. The patients were aged 46.2±12.8 years (mean±SD), and 72.4% of patient were female. The most common symptom and causal drug were jaundice (58.6%) and herbal medications (55.2%), respectively.

Results

Aspartate aminotransferase (AST), alanine aminotransferase, total bilirubin, alkaline phosphatase, and γ-glutamyl transpeptidase levels were 662.2±574.8 U/L, 905.4±794.9 U/L, 12.9±10.8 mg/dL, 195.8±123.3 U/L, and 255.3±280.8 U/L, respectively. According to serologic and histologic findings, 21 cases were diagnosed with DILI and 8 with AIH. The AIH group exhibited significantly higher AST levels (537.1±519.1 vs. 1043.3±600.5 U/L), globulin levels (2.7±0.4 vs. 3.3±0.5 g/dL), and prothrombin time (12.9±2.4 vs. 15.2±3.9 s; P<0.05). Antinuclear antibody was positive in 7 of 21 cases of DILI and all 8 cases of AIH (P=0.002). The simplified AIH score was 3.7±0.9 in the DILI group and 6.5±0.9 in the AIH group (P<0.001).

Conclusions

Accurate diagnosis is necessary for patients with a history of medication and visits for liver-function abnormalities; in particular, the possibility of AIH should be considered.

Citations

Citations to this article as recorded by  Crossref logo
  • Acute liver injury following methylprednisolone pulse therapy: 13 cases from a prospectively collected cohort
    Julian Allgeier, Sabine Weber, Rumyana Todorova, Jens Neumann, Alexander Gerbes
    European Journal of Gastroenterology & Hepatology.2022; 34(4): 457.     CrossRef
  • MODERN VIEW ON THE PROBLEM OF MEDICINAL LIVER LESIONS
    E. Yu Bibik, B. S Krivokolyisko, M. V Zolotarevskaya, O. A Churilin, Yu. S Venidiktova, N. G Zabolotnaya, N. G Samokish
    Journal of Volgograd State Medical University.2020; 17(4): 24.     CrossRef
  • VALUE OF TRANS-ABDOMINAL ULTRASOUND-GUIDED PERCUTANEOUS LIVER BIOPSY IN PATIENTS WITH FOCAL OR DIFFUSE LIVER LESIONS IN KURDISTAN CENTRE FOR GASTROENTEROLOGY AND HEPATOLOGY IN SULAIMANI CITY
    Dana Gharib, Mohammed Mohammed, Taha Al-Karboly, Heero Faraj, Kawa Mahmood, Nasr Qazi, Karok Salih, Omar Azeez
    JOURNAL OF SULAIMANI MEDICAL COLLEGE.2020; 10(2): 199.     CrossRef
  • Extrahepatic Autoimmune Diseases in Patients with Autoimmune Liver Diseases: A Phenomenon Neglected by Gastroenterologists
    Liping Guo, Lu Zhou, Na Zhang, Baoru Deng, Bangmao Wang
    Gastroenterology Research and Practice.2017; 2017: 1.     CrossRef
  • Ayurvedic drug induced liver injury
    Kunal K Dalal, Thomas Holdbrook, Steven R Peikin
    World Journal of Hepatology.2017; 9(31): 1205.     CrossRef
  • Liver enzyme abnormalities in taking traditional herbal medicine in Korea: A retrospective large sample cohort study of musculoskeletal disorder patients
    Jinho Lee, Joon-Shik Shin, Me-riong Kim, Jang-Hoon Byun, Seung-Yeol Lee, Ye-sle Shin, Hyejin Kim, Ki Byung Park, Byung-Cheul Shin, Myeong Soo Lee, In-Hyuk Ha
    Journal of Ethnopharmacology.2015; 169: 407.     CrossRef
  • Autoimmune hepatitis
    Farhad Sahebjam, John M. Vierling
    Frontiers of Medicine.2015; 9(2): 187.     CrossRef
  • Clinical Features of Drug-induced Liver Injury According to Etiology
    Byoung Moo Lee, Woong Cheul Lee, Jae Young Jang, Pyoung Ahn, Jin Nyoung Kim, Soung Won Jeong, Eui Ju Park, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim
    Journal of Korean Medical Science.2015; 30(12): 1815.     CrossRef
  • Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management
    John M. Vierling
    Clinical Gastroenterology and Hepatology.2015; 13(12): 2088.     CrossRef
  • Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease
    Agustin Castiella
    World Journal of Hepatology.2014; 6(4): 160.     CrossRef
  • 12,875 View
  • 140 Download
  • Crossref
Clinical significance of occult hepatitis B virus infection in chronic hepatitis C patients
Jae Young Jang, Soung Won Jeong, Sung Ran Cheon, Sae Hwan Lee, Sang Gyune Kim, Young Koog Cheon, Young Seok Kim, Young Deok Cho, Hong Soo Kim, So Young Jin, Yun Soo Kim, Boo Sung Kim
Korean J Hepatol 2011;17(3):206-212.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.206
Background/Aims

We investigated the frequency of occult hepatitis B virus (HBV) infection in anti-hepatitis C virus (HCV)-positive individuals and the effects of occult HBV infection on the severity of liver disease.

Methods

Seventy-one hepatitis B virus surface-antigen (HBsAg)-negative patients were divided according to their HBV serological status into groups A (anti-HBc positive, anti-HBs negative; n=18), B (anti-HBc positive, anti-HBs positive; n=34), and C (anti-HBc negative, anti-HBs positive/negative; n=19), and by anti-HCV positivity (anti-HCV positive; n=32 vs. anti-HCV negative; n=39). Liver biopsy samples were taken, and HBV DNA was quantified by real-time PCR.

Results

Intrahepatic HBV DNA was detected in 32.4% (23/71) of the entire cohort, and HBV DNA levels were invariably low in the different groups. Occult HBV infection was detected more frequently in the anti-HBc-positive patients. Intrahepatic HBV DNA was detected in 28.1% (9/32) of the anti-HCV-positive and 35.9% (14/39) of the anti-HCV-negative subjects. The HCV genotype did not affect the detection rate of intrahepatic HBV DNA. In anti-HCV-positive cases, occult HBV infection did not affect liver disease severity.

Conclusions

Low levels of intrahepatic HBV DNA were detected frequently in both HBsAg-negative and anti-HCV-positive cases. However, the frequency of occult HBV infection was not affected by the presence of hepatitis C, and occult HBV infection did not have a significant effect on the disease severity of hepatitis C.

Citations

Citations to this article as recorded by  Crossref logo
  • Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma
    Mohamed A. El-Maksoud, Maha R. Habeeb, Hayam F. Ghazy, Manal M. Nomir, Hatem Elalfy, Sally Abed, Maysaa E.S. Zaki
    European Journal of Gastroenterology & Hepatology.2019; 31(6): 716.     CrossRef
  • Occult Hepatitis B Virus infection in a cohort of patients with chronic Hepatitis C
    MA Amin, MI Naga, DA Algendy, AI El Badry, MM Fawzi
    Archives of Hepatitis Research.2019; 5(1): 017.     CrossRef
  • Occult Hepatitis B Infection in Hepatitis C Patients with Hematological Disorders
    Nematollah Jonaidi-Jafari, Mohammad Saeid Rezaee-Zavareh, Javad Tavallaei-Nosratabadi, Reza Ajudani, Mahdi Ramezani-Binabaj, Hamidreza Karimi-Sari, Morteza Izadi, Reza Ranjbar, Seyyed Mohammad Miri, Seyed Moayed Alavian
    Jundishapur Journal of Microbiology.2016;[Epub]     CrossRef
  • Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection
    Junhyeon Cho, Sang Soo Lee, Yun Suk Choi, Yejoo Jeon, Jung Wha Chung, Joo Yeong Baeg, Won Keun Si, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong
    World Journal of Gastroenterology.2016; 22(42): 9427.     CrossRef
  • Update on occult hepatitis B virus infection
    Manoochehr Makvandi
    World Journal of Gastroenterology.2016; 22(39): 8720.     CrossRef
  • Seroprevalence of occult hepatitis B among Egyptian paediatric hepatitis C cancer patients
    H. E. Raouf, A. S. Yassin, S. A. Megahed, M. S. Ashour, T. M. Mansour
    Journal of Viral Hepatitis.2015; 22(2): 103.     CrossRef
  • Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers
    Kyun-Hwan Kim, Hye-Young Chang, Jun Yong Park, Eun-Sook Park, Yong Kwang Park, Kwang-Hyub Han, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2014; 20(3): 251.     CrossRef
  • Occult Hepatitis B Virus Infection in Chronic Hepatitis C
    Jae Young Jang, Eui Ju Park
    The Korean Journal of Gastroenterology.2013; 62(3): 154.     CrossRef
  • The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis
    Mingyuan Zhang, Ruihong Wu, Jing Jiang, Gerald Y. Minuk, Junqi Niu
    Alcohol.2013; 47(7): 553.     CrossRef
  • Definition, Diagnosis, and Prevalence of Occult Hepatitis B Virus Infection
    Yun Soo Kim
    The Korean Journal of Gastroenterology.2013; 62(3): 143.     CrossRef
  • Detection of occult HBV infection by nested PCR assay among chronic hepatitis C patients with and without hepatocellular carcinoma
    Shereen E. Taha, Soha A. El-Hady, Tamer M. Ahmed, Iman Z. Ahmed
    Egyptian Journal of Medical Human Genetics.2013; 14(4): 353.     CrossRef
  • Clinical Characteristics of Occult HBV Infection and Impact on Treatment Response in Patients with Chronic Hepatitis C
    Sung Soo Byun, Jung Woo Shin, Myung Kwan Ko, Jung Min Hong, Kyung Hoon Kim, Mu Yeol Lee, Hye-Jeong Choi, Yoong Ki Jeong, Bo Ryung Park, Neung Hwa Park
    Korean Journal of Medicine.2012; 83(6): 731.     CrossRef
  • 11,003 View
  • 70 Download
  • Crossref
Case Report
Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
Jae Hee Lim, Yun Nah Lee, Young Seok Kim, Sang Gyune Kim, Seung Won Jeong, Jae Young Jang, Hong Soo Kim, Sae Hwan Lee, Tae Kwann Park
Korean J Hepatol 2011;17(1):61-65.
Published online March 21, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.1.61

Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of VKH disease is not well understood, an autoimmune T-cell response to a melanocyte-associated antigen is considered to be a cause of VKH disease. The complex immunological response to interferon and ribavirin may induce or exacerbate the autoimmune condition; however, VKH disease is a very rare complication associated with interferon therapy in chronic hepatitis C. We report a case of VKH disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.

Citations

Citations to this article as recorded by  Crossref logo
  • Enfermedad de Vogt Koyanagi Harada. Reporte de un caso y revisión de la literatura
    Rodrigo Betancourt, Stefanos A. Betancourt, Germán Soler, Rubén D. Mantilla, Gabriel A. Castillo
    Revista Colombiana de Reumatología.2020; 27(1): 50.     CrossRef
  • Vogt-Koyanagi-Harada disease. Case report and review of the literature
    Rodrigo Betancourt, Stefanos A. Betancourt, Germán Soler, Rubén D. Mantilla, Gabriel A. Castillo
    Revista Colombiana de Reumatología (English Edition).2020; 27(1): 50.     CrossRef
  • Ocular side effects of antirheumatic medications: a qualitative review
    Clara M Castillejo Becerra, Yue Ding, Beatrice Kenol, Andrew Hendershot, Alexa Simon Meara
    BMJ Open Ophthalmology.2020; 5(1): e000331.     CrossRef
  • Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature
    Jialiang Duan, Yang Wang, Danyan Liu, Jingxue Ma
    Ocular Immunology and Inflammation.2019; 27(2): 229.     CrossRef
  • Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature
    Ken Sato, Yuichi Yamazaki, Takeshi Kobayashi, Satoshi Takakusagi, Norio Horiguchi, Satoru Kakizaki, Masayasu Andou, Yoshihiro Matsuda, Toshio Uraoka, Hiroshi Ohnishi, Hiroaki Okamoto
    World Journal of Clinical Cases.2019; 7(9): 1043.     CrossRef
  • Vogt-Koyanagi-Harada disease
    Ghazala A. Datoo O'Keefe, Narsing A. Rao
    Survey of Ophthalmology.2017; 62(1): 1.     CrossRef
  • Exudative retinal detachment
    Radgonde Amer, Hilal Nalcı, Nilüfer Yalçındağ
    Survey of Ophthalmology.2017; 62(6): 723.     CrossRef
  • Vogt–Koyanagi–Harada syndrome: Perspectives for immunogenetics, multimodal imaging, and therapeutic options
    Sukhum Silpa-archa, Narumol Silpa-archa, Janine M. Preble, C. Stephen Foster
    Autoimmunity Reviews.2016; 15(8): 809.     CrossRef
  • Drug-Induced Ocular Adverse Reactions: Review of the Safety Alerts Issued During the Last Decade
    Ana Penedones, Diogo Mendes, Carlos Alves, Francisco Batel Marques
    Journal of Ocular Pharmacology and Therapeutics.2015; 31(5): 258.     CrossRef
  • Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies
    D. Saadoun, B. Bodaghi, B. Bienvenu, B. Wechsler, D. Sene, S. Trad, S. Abad, P. Cacoub, L. Kodjikian, P. Sève
    Autoimmunity Reviews.2013; 12(7): 774.     CrossRef
  • Probable Vogt–Koyanagi–Harada disease with initial unilateral ocular manifestation in a hepatitis C carrier
    Nikki Y. Far, David T. L. Liu
    Journal of Ophthalmic Inflammation and Infection.2012; 2(4): 235.     CrossRef
  • 11,712 View
  • 53 Download
  • Crossref